Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
38.4 /100
Rank 50 out of 131 Industries -
Advance/Decline
93/252
-
No. of Companies345
-
Avg. Market Cap12,876
-
Price to Earning Ratio9.96
-
Price to Earning Growth Ratio1.19
-
Price to Book Ratio28.75
-
Return on Equity4.92
-
Return on Capital Employed-
-
Return on Assets2.82
-
Dividend yield 1 year %0.83 %
-
Net Profit Growth Annual YoY %5.62 %
-
Net Profit Growth Qtr YoY %92.70 %
-
Net Profit Growth Qtr QoQ %180.25 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
362,598.4
|
205.1
|
L
 -0.6%
H
203.1
207.8
|
L
 -6.7%
H
203.1
224.4
|
L
 -8.8%
H
203.1
237.1
|
L
 -9.6%
H
203.1
237.1
|
L
 -3.3%
H
164.4
244.8
|
L
 31.4%
H
131.0
244.8
|
L
 98.3%
H
102.1
244.8
|
L
 262.5%
H
55.1
244.8
|
| Adc Therapeutics SA |
|
490.4
|
3.9
|
L
 -4.5%
H
3.8
4.1
|
L
 -6.5%
H
3.8
4.3
|
L
 -5.9%
H
3.8
5.0
|
L
 3.5%
H
3.3
5.0
|
L
 127.1%
H
1.1
5.0
|
L
 83.8%
H
0.4
6.0
|
L
 -86.2%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
3,722.1
|
11.8
|
L
 -4.1%
H
11.8
12.4
|
L
H
11.8
12.5
|
L
 -18.4%
H
11.8
14.8
|
L
 -5.9%
H
11.8
15.4
|
L
 31.3%
H
6.7
15.4
|
L
 727.3%
H
1.2
15.4
|
L
 65.0%
H
1.2
15.4
|
L
 -62.4%
H
1.2
37.2
|
| Annovis Bio Inc |
|
73.7
|
2.6
|
L
 -2.6%
H
2.5
2.7
|
L
 3.2%
H
2.3
3.0
|
L
 4.8%
H
2.3
3.0
|
L
 -28.8%
H
2.3
4.1
|
L
 44.4%
H
1.1
5.5
|
L
 -83.0%
H
1.1
23.9
|
L
 -93.2%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
1,856.5
|
5.0
|
L
 -0.4%
H
4.9
5.1
|
L
 1.0%
H
4.9
5.3
|
L
 -18.3%
H
4.9
6.3
|
L
 -27.2%
H
4.9
8
|
L
 -29.7%
H
4.3
8.7
|
L
 -34.2%
H
4.0
11.5
|
L
 -84.8%
H
4.0
34.5
|
L
 -81.4%
H
4.0
38.5
|
| Bristol-Myers Squibb |
|
117,056.5
|
57.5
|
L
 -1.1%
H
56.9
58.5
|
L
 -2.7%
H
56.9
60.8
|
L
 -5.2%
H
56.9
62.9
|
L
 6.1%
H
52.1
62.9
|
L
 -4.9%
H
42.5
62.9
|
L
 -14.5%
H
39.4
71.1
|
L
 -8.3%
H
39.4
81.4
|
L
 -8.5%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
424.0
|
8.2
|
L
 1.4%
H
8.0
8.2
|
L
 1.5%
H
7.9
8.4
|
L
 -25.1%
H
7.8
11.5
|
L
 -34.1%
H
7.8
14.1
|
L
 42.9%
H
4.0
14.1
|
L
 1.5%
H
1.4
15.1
|
L
 -91.0%
H
1.4
96.0
|
L
 -73.1%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
103,734.9
|
51.8
|
L
 -1.0%
H
51.5
52.4
|
L
 -2.9%
H
51.5
54.6
|
L
 -12.9%
H
51.5
59.9
|
L
 6.6%
H
47.6
61.7
|
L
 31.5%
H
32.4
61.7
|
L
 48.4%
H
31.7
61.7
|
L
 39.0%
H
28.5
61.7
|
L
 27.1%
H
28.5
61.7
|
| Johnson & Johnson |
|
566,915.3
|
235.4
|
L
 -0.9%
H
234.5
238.3
|
L
 -2.6%
H
234.5
245.1
|
L
 -2.9%
H
234.5
251.7
|
L
 14.1%
H
200.9
251.7
|
L
 44.4%
H
141.5
251.7
|
L
 52.9%
H
140.7
251.7
|
L
 47.1%
H
140.7
251.7
|
L
 118.9%
H
106.6
251.7
|
| Eli Lilly |
|
809,676.2
|
906.7
|
L
 -1.2%
H
899.3
925.4
|
L
 -8.0%
H
899.3
998.2
|
L
 -10.2%
H
899.3
1064.5
|
L
 -15.4%
H
899.3
1134.0
|
L
 7.6%
H
623.8
1134.0
|
L
 171.8%
H
323.3
1134.0
|
L
 392.0%
H
178.6
1134.0
|
L
 1177.9%
H
64.2
1134.0
|
| Merck & Company |
|
282,297.7
|
114.2
|
L
 0.0%
H
112.7
115.2
|
L
 -0.5%
H
112.7
116.8
|
L
 -6.6%
H
112.7
125.1
|
L
 13.0%
H
100.4
125.1
|
L
 20.5%
H
73.3
125.1
|
L
 7.9%
H
73.3
134.6
|
L
 54.4%
H
69.5
134.6
|
L
 129.0%
H
49.7
134.6
|
| Novo Nordisk (ADR) |
|
162,230.9
|
36.5
|
L
 -1.5%
H
36.2
37
|
L
 -3.8%
H
36.2
39.3
|
L
 -23.0%
H
35.9
41.1
|
L
 -24.0%
H
35.9
64.2
|
L
 -53.6%
H
35.9
81.4
|
L
 -49.1%
H
35.9
148.2
|
L
 3.9%
H
33.3
148.2
|
L
 33.8%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
278,647.4
|
146.0
|
L
 -1.5%
H
145.3
148.9
|
L
 -4.8%
H
145.3
155.8
|
L
 -10.2%
H
145.3
170.5
|
L
 7.3%
H
135.6
170.5
|
L
 29.0%
H
97.7
170.5
|
L
 75.0%
H
82.0
170.5
|
L
 69.9%
H
74.1
170.5
|
L
 127.2%
H
59.2
170.5
|
| Organon & Co. |
|
1,569.7
|
6.0
|
L
 -3.8%
H
6.0
6.3
|
L
 -5.0%
H
6.0
6.5
|
L
 -25.4%
H
6.0
8.2
|
L
 -11.7%
H
6.0
9.9
|
L
 -61.4%
H
6.0
15.9
|
L
 -73.1%
H
6.0
24.8
|
L
H
6.0
39.5
|
L
H
6.0
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,886.0
|
61.0
|
L
 1.6%
H
60.0
64.5
|
L
 -0.8%
H
60.0
64.5
|
L
 -12.4%
H
60.0
71.1
|
L
 -1.2%
H
60.0
71.1
|
L
 -27.7%
H
57.3
89.4
|
L
 -1.0%
H
56.0
90.0
|
L
 33.1%
H
42.7
90.0
|
L
 16.7%
H
26.3
90.0
|
| Pfizer |
|
153,415.0
|
27.0
|
L
 -1.6%
H
26.8
27.6
|
L
 1.5%
H
26.5
27.8
|
L
 1.2%
H
26.2
27.8
|
L
 7.1%
H
24.8
27.9
|
L
 3.0%
H
20.9
27.9
|
L
 -33.9%
H
20.9
42.2
|
L
 -24.1%
H
20.9
61.7
|
L
 -3.3%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,273.3
|
9.3
|
L
 -4.2%
H
9.2
9.7
|
L
 -0.5%
H
9.2
10.5
|
L
 -38.2%
H
9.2
15.0
|
L
 -30.1%
H
9.2
15.4
|
L
 -67.5%
H
9.2
28.4
|
L
 -73.5%
H
9.2
40.3
|
L
 -78.3%
H
9.2
50.9
|
L
 -92.8%
H
9.2
133.9
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,456.5
|
13.8
|
L
 -2.7%
H
13.8
14.1
|
L
 -2.6%
H
13.8
14.3
|
L
 -5.0%
H
13.8
14.8
|
L
 -3.0%
H
12.8
14.8
|
L
 1.3%
H
12.3
16.2
|
L
 26.0%
H
10.6
74.9
|
L
 16.6%
H
9.6
74.9
|
L
 46.1%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
56,328.4
|
17.8
|
L
 -1.6%
H
17.8
18.1
|
L
 0.3%
H
17.8
18.5
|
L
 -4.5%
H
17.5
18.8
|
L
 19.7%
H
14.9
18.8
|
L
 17.6%
H
13.0
18.8
|
L
 8.9%
H
12.6
18.8
|
L
 -10.0%
H
12.3
20.0
|
L
 -24.5%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
33,460.1
|
28.7
|
L
 -2.4%
H
28.5
29.8
|
L
 0.6%
H
28.5
30.3
|
L
 -16.0%
H
28.4
34.9
|
L
 -5.3%
H
28.4
37.3
|
L
 76.9%
H
12.5
37.3
|
L
 236.8%
H
7.1
37.3
|
L
 149.4%
H
6.8
37.3
|
L
 -46.9%
H
6.1
58.2
|
| Zoetis (Class A) |
|
48,827.5
|
115.7
|
L
 -0.3%
H
114.4
117.2
|
L
 0.0%
H
114.4
122.5
|
L
 -10.2%
H
114.4
132.3
|
L
 -5.4%
H
114.4
132.5
|
L
 -29.1%
H
114.4
172.2
|
L
 -30.2%
H
114.4
201.9
|
L
 -24.5%
H
114.4
249.3
|
L
 183.1%
H
40.9
249.3
|
| Biohaven Ltd |
|
1,343.3
|
8.9
|
L
 -0.3%
H
8.9
9.3
|
L
 -6.8%
H
8.8
10.0
|
L
 -20.5%
H
8.8
12.1
|
L
 -17.7%
H
8.8
14.0
|
L
 -68.3%
H
7.5
31.2
|
L
 -35.9%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Abeona Therapeutics Inc |
|
241.2
|
4.5
|
L
 -2.0%
H
4.4
4.6
|
L
 -6.5%
H
4.4
5
|
L
 -15.4%
H
4.4
5.6
|
L
 -12.9%
H
4.4
5.7
|
L
 -13.4%
H
3.9
7.5
|
L
 93.5%
H
2.3
9.0
|
L
 -91.8%
H
2.2
55
|
L
 -93.9%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,927.7
|
38.9
|
L
 0.2%
H
37.6
39.6
|
L
 -2.7%
H
37.6
42.9
|
L
 20.3%
H
31.3
42.9
|
L
 22.2%
H
25.2
42.9
|
L
 225.6%
H
5.5
42.9
|
L
 55.9%
H
2.2
53.9
|
L
 -22.4%
H
2.2
53.9
|
L
 -95.2%
H
2.2
939.6
|
| Acumen Pharma Inc |
|
161.7
|
2.7
|
L
 -8.6%
H
2.7
2.9
|
L
 -18.4%
H
2.7
3.6
|
L
 3.9%
H
2.5
3.6
|
L
 24.2%
H
1.7
3.6
|
L
 126.3%
H
0.9
3.6
|
L
 -28.8%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
815.5
|
4.2
|
L
 -3.0%
H
4.2
4.4
|
L
 -0.5%
H
4.1
4.5
|
L
 -0.7%
H
4.1
4.9
|
L
 -4.3%
H
3.5
5.1
|
L
 28.1%
H
2.7
5.1
|
L
 40.4%
H
1.7
5.1
|
L
 16.2%
H
1.7
6.5
|
L
 7.1%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
31.0
|
1.2
|
L
 -5.4%
H
1.2
1.4
|
L
 -3.9%
H
1.2
1.4
|
L
 -19.2%
H
1.2
1.7
|
L
 -44.3%
H
1.2
2.5
|
L
 84.9%
H
0.7
5.5
|
L
 -81.2%
H
0.4
9.6
|
L
 -97.2%
H
0.4
299.5
|
L
 -99.9%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,536.1
|
20.7
|
L
 0.1%
H
20.6
21.1
|
L
 0.6%
H
19.9
21.6
|
L
 -13.6%
H
19.9
25.4
|
L
 -23.6%
H
19.9
28.4
|
L
 20.7%
H
13.4
28.4
|
L
 5.0%
H
13.4
33.9
|
L
 -25.3%
H
12.2
33.9
|
L
 4.8%
H
12.2
58.7
|
| Adicet Bio Inc |
|
66.4
|
6.9
|
L
 -2.1%
H
6.8
7.1
|
L
 -4.0%
H
6.8
7.5
|
L
 -3.1%
H
6.7
8.1
|
L
 -12.4%
H
6.4
9.1
|
L
 -43.4%
H
6.4
17.4
|
L
 -93.3%
H
6.4
120
|
L
 -97.0%
H
6.4
349.9
|
L
H
6.4
349.9
|
| Achieve Life Sciences Inc |
|
212.9
|
4
|
L
 -2.2%
H
4.0
4.1
|
L
 -4.1%
H
4.0
4.3
|
L
 -6.3%
H
4.0
4.8
|
L
 -7.4%
H
3.9
6.0
|
L
 45.5%
H
1.8
6.0
|
L
 -8.7%
H
1.8
10.3
|
L
 -67.5%
H
1.8
12.6
|
L
 -99.8%
H
1.8
3123.8
|
| AC Immune SA |
|
286.7
|
2.9
|
L
 -3.4%
H
2.8
3.2
|
L
 -5.6%
H
2.8
3.4
|
L
 13.1%
H
2.4
3.4
|
L
 -5.9%
H
2.4
3.9
|
L
 31.9%
H
1.4
4
|
L
 31.9%
H
1.4
5.1
|
L
 -64.3%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
446.8
|
3.7
|
L
 -1.3%
H
3.6
3.8
|
L
 4.2%
H
3.5
3.9
|
L
 13.9%
H
2.8
3.9
|
L
 17.5%
H
2.5
4.9
|
L
 135.0%
H
1.1
4.9
|
L
 -53.6%
H
0.6
11.1
|
L
 -86.2%
H
0.6
30.4
|
L
 -76.5%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
52.4
|
1.7
|
L
 -2.4%
H
1.6
1.7
|
L
 2.5%
H
1.5
1.8
|
L
 8.5%
H
1.4
1.9
|
L
 -23.2%
H
1.4
3.6
|
L
 -67.7%
H
1.1
5.7
|
L
 -85.7%
H
1.1
14.4
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
14.1
|
0.8
|
L
 2.5%
H
0.8
0.9
|
L
 3.8%
H
0.8
0.9
|
L
 6.4%
H
0.8
1
|
L
 -24.6%
H
0.8
1.3
|
L
 66%
H
0.4
1.6
|
L
 43.1%
H
0.4
1.6
|
L
 -97.6%
H
0.4
35.8
|
L
 -98.7%
H
0.4
115
|
| Grace Therapeutics Inc |
|
68.4
|
4.4
|
L
 0.9%
H
4.4
4.7
|
L
 5.2%
H
4.2
4.7
|
L
 13.9%
H
3.6
4.7
|
L
 30%
H
3.3
4.7
|
L
 72.7%
H
1.8
4.7
|
L
 70%
H
1.7
5.0
|
L
 -86.5%
H
1.7
35.7
|
L
 -94.3%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
16.0
|
5.6
|
L
 -15.5%
H
5.4
6.6
|
L
 44.3%
H
3.9
7.5
|
L
 237.4%
H
1.3
7.5
|
L
 68.2%
H
1.3
7.5
|
L
 -33.2%
H
1.3
21
|
L
 -90.8%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
2.9
|
2
|
L
 7.0%
H
1.9
2.1
|
L
 2.0%
H
1.7
2.1
|
L
 -18.4%
H
1.5
2.7
|
L
 -66.8%
H
1.5
6.8
|
L
 -88.9%
H
1.5
30.3
|
L
 -99.2%
H
1.5
350
|
L
 -99.9%
H
1.5
3175
|
L
H
1.5
5900
|
| Agios Pharma Inc |
|
1,632.4
|
27.9
|
L
 -0.2%
H
27.5
28.4
|
L
 0.0%
H
27.5
29.5
|
L
 -4.8%
H
26.8
31.0
|
L
 13.9%
H
24.2
31.0
|
L
 -14.8%
H
22.2
46
|
L
 22.6%
H
19.8
62.6
|
L
 -44.7%
H
16.8
62.6
|
L
 -22.8%
H
16.8
99.8
|
| Akebia Therapeutics Inc |
|
380.4
|
1.4
|
L
H
1.4
1.5
|
L
 -2.7%
H
1.4
1.6
|
L
 20.3%
H
1.2
1.6
|
L
 -14.5%
H
1.1
1.7
|
L
 -30.4%
H
1.1
4.1
|
L
 108.8%
H
0.5
4.1
|
L
 -59.5%
H
0.2
4.3
|
L
 -83.6%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
42.1
|
6.8
|
L
 -7.2%
H
6.8
7.6
|
L
 -10.0%
H
6.8
8.1
|
L
 0.2%
H
6.3
8.1
|
L
 -36.2%
H
6.2
11.5
|
L
 -40.9%
H
3.8
13.7
|
L
 -78.4%
H
3.8
46.3
|
L
 -98.9%
H
3.8
857.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
4,691.2
|
28.2
|
L
 -0.9%
H
27.9
28.9
|
L
 1.4%
H
27
28.9
|
L
 -11.8%
H
27
33.9
|
L
 -1.1%
H
27
35.3
|
L
 -17.0%
H
25.2
36.3
|
L
 5.7%
H
22.0
36.5
|
L
 40.4%
H
18.4
36.5
|
L
 -6.8%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
17.4
|
1.1
|
L
 -1.8%
H
1.0
1.1
|
L
 -14.3%
H
1.0
1.3
|
L
 17.4%
H
0.9
1.4
|
L
 4.9%
H
0.8
1.4
|
L
 12.5%
H
0.6
2.1
|
L
 -100.0%
H
0.1
3612
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
41,401.0
|
312.2
|
L
 0.3%
H
311.1
322.4
|
L
 -0.4%
H
309.7
327.0
|
L
 -7.1%
H
309.6
341.4
|
L
 -22%
H
298
427.1
|
L
 23.1%
H
205.9
495.6
|
L
 66.5%
H
142.0
495.6
|
L
 116.5%
H
117.6
495.6
|
L
 422.0%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
32.6
|
1.2
|
L
 -4.6%
H
1.2
1.4
|
L
 -4.6%
H
1.2
1.5
|
L
 2.5%
H
1.1
1.5
|
L
 -12.7%
H
1.0
1.6
|
L
 -35.8%
H
1.0
2.4
|
L
 -11.4%
H
1.0
7.4
|
L
 -96.3%
H
1.0
35.2
|
L
H
1.0
309.6
|
| Alzamend Neuro Inc |
|
7.0
|
1.8
|
L
 -3.2%
H
1.7
1.9
|
L
 -10.3%
H
1.7
2.4
|
L
 -7.1%
H
1.7
2.4
|
L
 -13.3%
H
1.6
2.5
|
L
 -79.2%
H
1.6
10.2
|
L
 -99.6%
H
1.6
1071.9
|
L
H
1.6
45292.5
|
L
H
1.6
45292.5
|
| Amylyx Pharma Inc |
|
1,526.5
|
13.8
|
L
 -1.7%
H
13.7
14.4
|
L
 -1.3%
H
13.7
14.8
|
L
 -1.4%
H
13.5
15.7
|
L
 14.9%
H
10.8
17.5
|
L
 270.2%
H
3.1
17.5
|
L
 -56.5%
H
1.6
32.7
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
884.7
|
19.5
|
L
 -0.2%
H
19.2
19.8
|
L
 7.3%
H
18.7
20
|
L
 -31.7%
H
17.0
28.8
|
L
 -26.7%
H
17.0
29.5
|
L
 -30.1%
H
17.0
31.3
|
L
 -47.6%
H
17.0
67.7
|
L
 7.9%
H
16.9
67.7
|
L
 67.5%
H
11.4
67.7
|
| Annexon Inc |
|
761.7
|
5.1
|
L
 -6.9%
H
5.1
5.6
|
L
 -9.7%
H
5.1
5.9
|
L
 4.3%
H
4.8
6.3
|
L
 -1.2%
H
4.5
7.2
|
L
 105.2%
H
1.3
7.2
|
L
 24.6%
H
1.3
8.4
|
L
 -82.9%
H
1.3
30.9
|
L
H
1.3
38.0
|
| Apollomics Inc (Class A) |
|
39.7
|
18.5
|
L
 -3.2%
H
18.3
18.7
|
L
 -7.1%
H
18.3
20.1
|
L
 -7.2%
H
18.3
21.5
|
L
 10.6%
H
16.3
24.2
|
L
 78.0%
H
3.7
42.1
|
L
 -98.4%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
2,200.0
|
17.2
|
L
 -4.2%
H
17.2
18.1
|
L
 -9.1%
H
17.2
19.4
|
L
 -22.8%
H
17.2
22.8
|
L
 -30.2%
H
17.2
27.5
|
L
 -28.7%
H
16.1
30.5
|
L
 -72.7%
H
16.1
94.8
|
L
 -60.8%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Aptorum Grp Ltd (Class A) |
|
8.8
|
1.1
|
L
 14.9%
H
0.9
1.1
|
L
 36.7%
H
0.8
1.1
|
L
 36.7%
H
0.8
1.1
|
L
 -4.4%
H
0.7
1.2
|
L
 17.4%
H
0.7
4.5
|
L
 -53.8%
H
0.5
17.5
|
L
 -96.7%
H
0.5
35.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
5.9
|
0.8
|
L
H
0.7
0.8
|
L
 2.7%
H
0.7
0.8
|
L
H
0.7
1.0
|
L
 -18.3%
H
0.6
1.5
|
L
 -68.6%
H
0.6
2.4
|
L
 -85.2%
H
0.6
8.9
|
L
 -99.3%
H
0.6
156
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
485.7
|
4.0
|
L
 -2.0%
H
4.0
4.1
|
L
 -1%
H
4.0
4.3
|
L
 0.8%
H
3.9
4.5
|
L
 -31.4%
H
2.9
6.6
|
L
 28.0%
H
2.1
7.6
|
L
 403.8%
H
0.8
7.6
|
L
 -23.0%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
188.4
|
6.6
|
L
 -1.3%
H
6.5
6.8
|
L
 -0.8%
H
6.4
6.8
|
L
 -13.6%
H
6.4
8.7
|
L
 1.5%
H
6.0
8.7
|
L
 -48.4%
H
5.9
24.2
|
L
 -56.8%
H
5.9
45
|
L
 -85.7%
H
5.9
65
|
L
 -76.5%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,302.3
|
5.3
|
L
 -3.5%
H
5.3
5.5
|
L
 -8.1%
H
5.3
5.9
|
L
 -7.3%
H
5.3
6.8
|
L
 -6.5%
H
5.3
8.4
|
L
 -3.3%
H
3.2
8.4
|
L
 36.9%
H
3.2
10.1
|
L
 -23.7%
H
0.5
10.1
|
L
 -25.9%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
2,754.8
|
22.2
|
L
 -3.1%
H
22.1
23.3
|
L
 -2.4%
H
21.9
23.3
|
L
 -12.6%
H
21.9
28.8
|
L
 -20.7%
H
21.9
30.8
|
L
 32.4%
H
11.9
31.8
|
L
 92.0%
H
1.8
31.8
|
L
 -28.0%
H
1.8
36.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
5.6
|
8.0
|
L
 11.3%
H
7.6
9.8
|
L
 112.0%
H
3.8
9.8
|
L
 101.3%
H
3.2
9.8
|
L
 69.2%
H
3.2
9.8
|
L
 -55.2%
H
3.2
85.8
|
L
 -78.9%
H
3.2
85.8
|
L
 -98.6%
H
3.2
567
|
L
H
3.2
46656
|
| Assembly Biosciences Inc |
|
450.2
|
28.5
|
L
 3.5%
H
27.7
30.1
|
L
 1.2%
H
27.1
30.1
|
L
 -1.0%
H
27
30.6
|
L
 -19.3%
H
24.7
39.0
|
L
 166.2%
H
7.8
39.7
|
L
 92.8%
H
7.7
39.7
|
L
 -51.1%
H
7.7
59.2
|
L
 -57.6%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
528.0
|
4.2
|
L
 -3.4%
H
4.0
4.4
|
L
 -20.1%
H
4.0
5.5
|
L
 -18.9%
H
4.0
6.5
|
L
 -30.6%
H
4.0
8.6
|
L
 -0.5%
H
3.9
14.5
|
L
 251.7%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
85.9
|
13.4
|
L
 -2.6%
H
13.0
13.8
|
L
 15.9%
H
11.3
13.9
|
L
 12.9%
H
11.1
13.9
|
L
 23.8%
H
8.6
13.9
|
L
 25.4%
H
7.7
15.2
|
L
 -84.6%
H
7.7
120.2
|
L
 -76.1%
H
7.7
120.2
|
L
 -98.3%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,267.6
|
3.5
|
L
 -2.2%
H
3.4
3.6
|
L
 -5.4%
H
3.4
3.9
|
L
 -10.1%
H
3.4
4.4
|
L
 -11.9%
H
3.3
4.7
|
L
 154.7%
H
1.2
6.8
|
L
 193.3%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
53.4
|
2.8
|
L
H
2.7
2.8
|
L
 -2.8%
H
2.7
3.1
|
L
 -22.2%
H
2.7
3.9
|
L
 -59.3%
H
2.7
6.9
|
L
 -73.2%
H
2.7
174.6
|
L
 -99.3%
H
2.7
513
|
L
 -100.0%
H
2.7
49571
|
L
H
2.7
49571
|
| Atossa Therapeutics Inc |
|
45.9
|
5.3
|
L
 3.9%
H
5.1
6.0
|
L
 6.4%
H
4.9
6.0
|
L
 26.6%
H
3.8
6.0
|
L
 -51.4%
H
3.8
11.2
|
L
 -50.4%
H
3.8
19.4
|
L
 -46.2%
H
3.8
34.7
|
L
 -87.2%
H
3.8
147
|
L
 -99.4%
H
3.8
1133.7
|
| Atara Biotherapeutics Inc |
|
68.3
|
4.9
|
L
 -4.1%
H
4.8
5.3
|
L
 -24.5%
H
4.8
6.5
|
L
 17.5%
H
3.9
7.3
|
L
 -71.4%
H
3.9
19.1
|
L
 -27.2%
H
3.9
19.1
|
L
 -93.4%
H
0.4
79.3
|
L
 -98.7%
H
0.4
501
|
L
 -98.8%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
450.9
|
5.7
|
L
 -5.7%
H
5.6
6.1
|
L
 -7.2%
H
5.6
6.2
|
L
 21.7%
H
4.5
6.5
|
L
 80.3%
H
3.1
6.5
|
L
 79.7%
H
2.5
6.5
|
L
 61.7%
H
2.5
6.5
|
L
 -92.8%
H
2.5
78.7
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
248.4
|
13.4
|
L
 -5.6%
H
13.2
14.8
|
L
 -15.1%
H
13.2
16.4
|
L
 -5.6%
H
13.2
19.1
|
L
 -27.9%
H
13.0
20.0
|
L
 63.3%
H
3.4
20.7
|
L
 521.3%
H
0.0
34.5
|
L
 -65.2%
H
0.0
44.4
|
L
 -73.6%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
28.0
|
2.6
|
L
 0.8%
H
2.6
2.7
|
L
 2.8%
H
2.6
2.7
|
L
 13.5%
H
2.2
2.7
|
L
 2.4%
H
2.1
3.1
|
L
 108.8%
H
1.0
3.1
|
L
 27.9%
H
1.0
3.5
|
L
 -98.7%
H
1.0
193
|
L
 -100.0%
H
1.0
672000
|
| Adagene Inc (ADR) |
|
171.1
|
3.6
|
L
 -1.6%
H
3.5
3.9
|
L
 -12.1%
H
3.5
4.5
|
L
 15.6%
H
2.8
4.6
|
L
 99.5%
H
1.5
4.6
|
L
 103.9%
H
1.3
4.6
|
L
 134.2%
H
1.1
4.6
|
L
 -82.7%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.0
|
5.7
|
L
 -2.9%
H
5.7
5.7
|
L
 -17.7%
H
5.6
6.9
|
L
 -21.5%
H
5.6
8.0
|
L
 -27.7%
H
5.6
10.4
|
L
 -26.1%
H
5.6
12.1
|
L
 -76.2%
H
5
27.9
|
L
 -97.4%
H
5
229.6
|
L
H
5
750.4
|
| Amarin Corp (ADR) |
|
301.4
|
14.5
|
L
 -3.4%
H
14.3
15.0
|
L
 -5.5%
H
14.3
15.8
|
L
 -7.1%
H
13.5
17
|
L
 5%
H
13.1
17.3
|
L
 3193.2%
H
0.4
20.9
|
L
 822.9%
H
0.4
20.9
|
L
 125%
H
0.4
20.9
|
L
 906.3%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
13,621.9
|
221.9
|
L
 -0.9%
H
221.3
226.2
|
L
 -1.8%
H
219.8
232
|
L
 -1.4%
H
219.6
248.6
|
L
 11.0%
H
188.1
248.6
|
L
 35.9%
H
124.1
248.6
|
L
 102.1%
H
64.3
248.6
|
L
 53.6%
H
61.6
248.6
|
L
 1156.4%
H
11.9
248.6
|
| Alterity Therapeutics Ltd (ADR) |
|
59.6
|
3.3
|
L
 -4.6%
H
3.3
3.5
|
L
 -8.6%
H
3.3
3.7
|
L
 -0.3%
H
3.3
3.8
|
L
 6.5%
H
2.9
3.8
|
L
 -16.1%
H
2.5
7
|
L
 20.5%
H
1
7
|
L
 -79.7%
H
1
27.5
|
L
 -89.6%
H
1
66.9
|
| Astrazeneca plc |
|
569,264.1
|
183.6
|
L
 -2.8%
H
182.6
188.4
|
L
 -3.3%
H
182.6
194.0
|
L
 -10.1%
H
182.6
209.9
|
L
 -2.6%
H
182.6
212.7
|
L
 -2.6%
H
182.6
212.7
|
L
 -2.6%
H
182.6
212.7
|
L
 -2.6%
H
182.6
212.7
|
L
 -2.6%
H
182.6
212.7
|
| Biofrontera Inc |
|
10.1
|
0.9
|
L
 1.2%
H
0.8
0.9
|
L
H
0.8
1.0
|
L
 -2.3%
H
0.8
1.0
|
L
 13.0%
H
0.6
1.0
|
L
 -15.5%
H
0.5
1.2
|
L
 -93.1%
H
0.5
13.5
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biomea Fusion Inc |
|
80.6
|
1.1
|
L
 4.6%
H
1.1
1.2
|
L
 -16.2%
H
1.1
1.4
|
L
 -13.6%
H
1.1
1.6
|
L
 -18.6%
H
1.0
1.7
|
L
 -58.8%
H
0.9
3.1
|
L
 -92.5%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
9.1
|
4.8
|
L
 4.9%
H
4.5
4.9
|
L
 21.7%
H
4.0
4.9
|
L
 -5.7%
H
3.9
5.3
|
L
 -7.8%
H
3.9
7.2
|
L
 -45.9%
H
3.9
9.7
|
L
 -83.4%
H
3.9
40.6
|
L
 -99.4%
H
3.9
755.8
|
L
H
3.9
861.4
|
| Blue Water Biotech Inc |
|
11.0
|
0.6
|
L
 29.2%
H
0.5
0.6
|
L
 14.8%
H
0.5
0.6
|
L
 -18.4%
H
0.4
1.0
|
L
 -65.0%
H
0.4
2.3
|
L
 675%
H
0.1
5.9
|
L
 -40.4%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
65.8
|
1.6
|
L
 2.6%
H
1.5
1.7
|
L
 -5.3%
H
1.5
1.9
|
L
 23.1%
H
1.2
1.9
|
L
 -31.9%
H
1.2
2.2
|
L
 -4.2%
H
1.0
3.4
|
L
 37.9%
H
0.7
4
|
L
 -87.1%
H
0.5
33
|
L
H
0.5
48.5
|
| Biodexa Pharma PLC (ADR) |
|
0.6
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 -15.7%
H
0.7
0.9
|
L
 -39.7%
H
0.7
1.2
|
L
 -80.8%
H
0.7
3.6
|
L
 -96.5%
H
0.7
19.4
|
L
 -100.0%
H
0.7
815034.7
|
L
 -100.0%
H
0.7
36100000
|
L
 -100.0%
H
0.7
2720000000
|
| BeiGene Ltd (ADR) |
|
29,324.5
|
275.3
|
L
 -2.6%
H
275.0
285.5
|
L
 -3.1%
H
275.0
293.1
|
L
 -24.0%
H
275.0
372.7
|
L
 -12.9%
H
275.0
372.7
|
L
 20.5%
H
228.9
385.2
|
L
 23.4%
H
127.0
385.2
|
L
 -21.1%
H
118.2
426.6
|
L
 894.1%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
11.5
|
2.7
|
L
 -2.2%
H
2.5
2.7
|
L
 -0.8%
H
2.5
2.8
|
L
 -8.6%
H
2.5
3.0
|
L
 -12.8%
H
2.5
3.2
|
L
 -22.5%
H
2.3
7.8
|
L
 -89.5%
H
0.1
101.2
|
L
 -97.8%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
5,599.0
|
154.6
|
L
 -2.9%
H
153
160.0
|
L
 -5.8%
H
153
166.3
|
L
 -14.6%
H
153
192.3
|
L
 -0.9%
H
146.1
200
|
L
 128.2%
H
49
200
|
L
 424.0%
H
11
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
24.9
|
4.6
|
L
 4.8%
H
4.4
4.7
|
L
 1.5%
H
4.3
4.7
|
L
 6.0%
H
4.1
4.9
|
L
 18.5%
H
3.6
4.9
|
L
 -11%
H
3.6
21.4
|
L
 78.0%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
1,669.5
|
29.1
|
L
 -6.6%
H
29.1
32.5
|
L
 -4.6%
H
29.1
32.5
|
L
 2.1%
H
25.1
36.5
|
L
 4.6%
H
21.1
36.5
|
L
 102.7%
H
4.3
40.4
|
L
 549.6%
H
2.7
40.4
|
L
 443.9%
H
2.6
40.4
|
L
 11.9%
H
0.9
54
|
| Cullinan Oncology Inc |
|
771.1
|
12.7
|
L
 -2.6%
H
12.7
13.2
|
L
 -5.6%
H
12.7
14.5
|
L
 -6.7%
H
12.7
16.7
|
L
 31.6%
H
9.4
16.7
|
L
 46.1%
H
5.7
16.7
|
L
 17.1%
H
5.7
30.2
|
L
 -69.0%
H
5.7
43.5
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
227.8
|
1.5
|
L
 -5.6%
H
1.5
1.6
|
L
 -6.8%
H
1.5
1.7
|
L
 -6.8%
H
1.5
2.1
|
L
 11.8%
H
1.3
2.6
|
L
 60%
H
0.7
2.6
|
L
 -75.7%
H
0.7
8.7
|
L
 -90.2%
H
0.7
19.3
|
L
 -92.2%
H
0.7
32.0
|
| Cingulate Inc |
|
80.7
|
7.4
|
L
 -1.7%
H
6.6
8.0
|
L
 -15.1%
H
6.6
11.9
|
L
 25.3%
H
5.8
11.9
|
L
 85.9%
H
3.9
11.9
|
L
 80.4%
H
3.2
11.9
|
L
 702.2%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
62.7
|
5.3
|
L
 -9.4%
H
5.2
6.1
|
L
 -7.0%
H
5.2
6.7
|
L
 14.7%
H
4.4
6.7
|
L
 -20.4%
H
3.9
7.0
|
L
 24.6%
H
2.3
13.5
|
L
 -77.5%
H
2.3
24.8
|
L
 -98.0%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
13.7
|
3.2
|
L
 1.9%
H
3.0
3.2
|
L
 1.3%
H
3.0
3.4
|
L
 -4.1%
H
2.6
3.7
|
L
 20.9%
H
2.5
4.1
|
L
 -71.6%
H
2.5
20.6
|
L
 -92.8%
H
2.5
133.5
|
L
 -99.4%
H
2.5
573
|
L
 -100.0%
H
2.5
15300
|
| Clearmind Medicine Inc |
|
1.4
|
0.7
|
L
H
0.6
0.7
|
L
 -15.4%
H
0.6
0.9
|
L
 -43.6%
H
0.6
1.3
|
L
 -75.9%
H
0.6
2.8
|
L
 -98.6%
H
0.6
52.4
|
L
 -100.0%
H
0.6
3780
|
L
 -100.0%
H
0.6
788400
|
L
H
0.6
788400
|
| Compass Therapeutics Inc |
|
927.5
|
5.2
|
L
 -4.5%
H
5.1
5.4
|
L
 -0.8%
H
5.1
5.5
|
L
 -16.5%
H
5.1
6.2
|
L
 3.2%
H
4.8
6.9
|
L
 129.9%
H
1.3
6.9
|
L
 60.4%
H
0.8
6.9
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
1.4
|
2.3
|
L
 5.5%
H
2.2
2.3
|
L
 -6.2%
H
2.1
2.5
|
L
 -28.7%
H
2.1
3.6
|
L
 -64.8%
H
2.1
8.9
|
L
 -94.7%
H
2.1
45.8
|
L
 -100.0%
H
2.1
6600000
|
L
 -100.0%
H
2.1
125550000
|
L
H
2.1
256050000
|
| Context Therapeutics Inc |
|
264.6
|
2.9
|
L
 -3.7%
H
2.8
3
|
L
 -14.3%
H
2.7
3.6
|
L
 28.6%
H
2.1
3.6
|
L
 126.8%
H
1.1
3.6
|
L
 274.0%
H
0.5
3.6
|
L
 336.4%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
14.2
|
1.0
|
L
 -5.5%
H
1.0
1.1
|
L
H
1
1.1
|
L
 2.0%
H
1.0
1.1
|
L
 4.0%
H
0.9
1.2
|
L
 -33.6%
H
0.9
2.7
|
L
 -44.0%
H
0.9
3.3
|
L
 -94.6%
H
0.9
41.5
|
L
 -99.5%
H
0.9
309.6
|
| Collegium pharma Inc |
|
1,125.3
|
35.4
|
L
 -2.4%
H
35.3
36.6
|
L
 2.7%
H
34.7
37.1
|
L
 -21.2%
H
34.3
46.4
|
L
 -27.5%
H
34.3
50.8
|
L
 18.4%
H
23.2
50.8
|
L
 47.4%
H
20.8
50.8
|
L
 37.8%
H
14.0
50.8
|
L
 123.9%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
3,684.8
|
34.6
|
L
 1.6%
H
34.5
36.4
|
L
 7.7%
H
32.0
36.4
|
L
 -0.5%
H
31.8
38.2
|
L
 -58.6%
H
28.7
85.3
|
L
 -39.9%
H
28.7
117.3
|
L
 65.7%
H
20.8
117.3
|
L
 35.2%
H
15.8
117.3
|
L
 696.3%
H
4.1
117.3
|
| Cosmos Health Inc |
|
12.7
|
0.3
|
L
 6.3%
H
0.3
0.3
|
L
 -5.6%
H
0.3
0.4
|
L
 -8.1%
H
0.3
0.4
|
L
 -30.6%
H
0.3
0.6
|
L
 -33.3%
H
0.3
1.3
|
L
 -88.9%
H
0.3
4.1
|
L
 -99.7%
H
0.3
194.3
|
L
 -99.8%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
42.3
|
2.8
|
L
 -1.7%
H
2.8
2.9
|
L
 -6.9%
H
2.7
3.4
|
L
 -27.4%
H
2.7
5.0
|
L
 -35.8%
H
2.7
5.4
|
L
 -42.0%
H
1.9
6.3
|
L
 41.5%
H
1.0
7.3
|
L
 -14.2%
H
1.0
7.5
|
L
 -34.8%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
2,783.2
|
22.8
|
L
 2.1%
H
22.2
22.9
|
L
 -1.9%
H
22.2
23.6
|
L
 -6.2%
H
22.2
25.4
|
L
 -4%
H
22.1
25.5
|
L
 -1.6%
H
19.1
26.6
|
L
 39.0%
H
11.1
26.6
|
L
 421.5%
H
4.2
26.6
|
L
 1934.8%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
151.0
|
8.6
|
L
 -3.8%
H
8.6
9.1
|
L
 -8.6%
H
8.6
10.1
|
L
 15.9%
H
7.3
10.5
|
L
 5.9%
H
7.2
10.5
|
L
 43.3%
H
4.6
20.6
|
L
 24.5%
H
3.0
61.9
|
L
 -87.8%
H
2.1
71.7
|
L
 -83.8%
H
2.1
323.4
|
| Crinetics Pharma Inc |
|
3,724.4
|
35.6
|
L
 -0.7%
H
35.1
36.0
|
L
 -5.1%
H
35.1
38.5
|
L
 -18.1%
H
35.1
45.2
|
L
 -25.9%
H
35.1
58.0
|
L
 3.6%
H
24.1
58.0
|
L
 111.1%
H
15.2
62.5
|
L
 115.7%
H
14.8
62.5
|
L
H
10.6
62.5
|
| Corvus Pharma Inc |
|
1,119.6
|
13.3
|
L
 -5.4%
H
13.0
14.4
|
L
 -13.0%
H
13.0
15.9
|
L
 -19.6%
H
13.0
18.7
|
L
 78.0%
H
6.4
27.0
|
L
 216.6%
H
2.5
27.0
|
L
 1860.3%
H
0.6
27.0
|
L
 334.2%
H
0.6
27.0
|
L
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
757.3
|
4.5
|
L
 -6.9%
H
4.4
4.8
|
L
 -4.9%
H
4.4
8.2
|
L
 -18.1%
H
4.4
8.2
|
L
 11.3%
H
3.9
8.2
|
L
 564.2%
H
0.4
8.2
|
L
 141.8%
H
0.4
8.2
|
L
 -46.2%
H
0.4
10.1
|
L
 -64.2%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
4.6
|
0.9
|
L
 2.2%
H
0.9
1.0
|
L
 14.6%
H
0.8
1.0
|
L
 -9.6%
H
0.7
1.1
|
L
 -32.4%
H
0.7
1.7
|
L
 -98.7%
H
0.7
100.8
|
L
 -100.0%
H
0.7
3168
|
L
 -100.0%
H
0.7
30564
|
L
 -100.0%
H
0.7
784800
|
| Cyclerion Therapeutics Inc |
|
6.1
|
1.6
|
L
 5.3%
H
1.4
1.6
|
L
 9.7%
H
1.3
1.6
|
L
 18.7%
H
1.2
1.6
|
L
 9.7%
H
1.0
2.3
|
L
 -41.3%
H
1.0
3.8
|
L
 -85.4%
H
1.0
12.0
|
L
 -98.0%
H
1.0
97.2
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
7,599.1
|
61.7
|
L
 -2.0%
H
61.0
64.0
|
L
 2.7%
H
59.2
64.0
|
L
 -9.2%
H
58.4
70.4
|
L
 -1.6%
H
58.4
71.0
|
L
 43.2%
H
29.3
71.0
|
L
 75.3%
H
26.0
110
|
L
 148.2%
H
17.7
110
|
L
 893.6%
H
5.8
110
|
| Cellectis (ADR) |
|
336.0
|
3.3
|
L
 -4.0%
H
3.2
3.4
|
L
 -2.3%
H
3.2
3.7
|
L
 -14.4%
H
3.2
4.3
|
L
 -23.6%
H
3.2
5.1
|
L
 163.0%
H
1.1
5.5
|
L
 75.8%
H
1.0
5.5
|
L
 -84.4%
H
1.0
22.2
|
L
 -87.7%
H
1.0
38.9
|
| Centessa Pharma PLC (ADR) |
|
4,000.0
|
27.1
|
L
 -4.5%
H
26.7
28.8
|
L
 2.8%
H
26.3
29.2
|
L
 10.5%
H
24.4
29.2
|
L
 8.9%
H
21.5
29.2
|
L
 66.1%
H
9.6
30.6
|
L
 593.8%
H
3.4
30.6
|
L
H
2.9
30.6
|
L
H
2.9
30.6
|
| Connect Biopharma Holdings Ltd (ADR) |
|
153.8
|
2.8
|
L
 -3.8%
H
2.7
2.9
|
L
 2.6%
H
2.6
3
|
L
 4.2%
H
2.4
3.0
|
L
 21.6%
H
2.0
3.2
|
L
 236.6%
H
0.5
3.3
|
L
 109.1%
H
0.5
3.3
|
L
 -85.1%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
19.4
|
1.4
|
L
 4.6%
H
1.3
1.4
|
L
 -5.6%
H
1.3
1.5
|
L
 -17.6%
H
1.3
1.7
|
L
 -34.9%
H
1.3
2.2
|
L
 -52.8%
H
1.3
9.2
|
L
 -88.3%
H
0.3
13.2
|
L
 -94.4%
H
0.3
30.1
|
L
 -99.5%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
2,214.7
|
21.4
|
L
 0.2%
H
21.3
21.4
|
L
 0.6%
H
21.3
21.4
|
L
 82%
H
10.0
21.4
|
L
 132.0%
H
8.4
21.4
|
L
 157.4%
H
5.6
21.4
|
L
 16.8%
H
5.6
21.4
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
220.5
|
6.6
|
L
 -4.6%
H
6.6
7.1
|
L
 -8.2%
H
6.6
7.8
|
L
 -22%
H
6.6
9.1
|
L
 -15.8%
H
6.6
9.6
|
L
 19.0%
H
5.5
9.6
|
L
 345.0%
H
1.0
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
4.0
|
L
 -5.0%
H
3.9
4.3
|
L
 -5.4%
H
3.9
4.6
|
L
 -13.2%
H
3.6
5.1
|
L
 -47.1%
H
3.6
8.6
|
L
 -54.2%
H
3.6
13.1
|
L
 -55.2%
H
3.6
14.4
|
L
 -94.7%
H
3.6
80.3
|
L
 -100.0%
H
3.6
17437.5
|
| DiaMedica Therapeutics Inc |
|
352.0
|
6.8
|
L
 -3.7%
H
6.7
7.0
|
L
 -7.1%
H
6.7
7.4
|
L
 -19.7%
H
6.7
8.7
|
L
 -20.3%
H
6.7
9.0
|
L
 31.5%
H
3.2
10.4
|
L
 286.3%
H
1.5
10.4
|
L
 -32.4%
H
1.1
10.7
|
L
 154.1%
H
1.1
13.8
|
| Dermata Therapeutics Inc |
|
4.1
|
1.5
|
L
 20.7%
H
1.4
1.8
|
L
 22.7%
H
1.2
1.8
|
L
 8.2%
H
1.1
1.8
|
L
 -31.8%
H
1.1
4.7
|
L
 23.7%
H
0.6
7.1
|
L
 -8.2%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
1,062.5
|
19.1
|
L
 -1.9%
H
18.9
20.1
|
L
 -7.0%
H
18.9
20.7
|
L
 -11.0%
H
18.6
24.1
|
L
 -16.1%
H
16.5
25.4
|
L
 261.6%
H
3.9
26.2
|
L
 24.0%
H
0.5
26.2
|
L
 -65.7%
H
0.5
68.8
|
L
 -93.8%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
61.4
|
7.4
|
L
 1.7%
H
6.7
9.4
|
L
 23.3%
H
4.9
9.4
|
L
 818.8%
H
0.8
9.4
|
L
 396.6%
H
0.7
9.4
|
L
 197.6%
H
0.7
9.4
|
L
 -2.8%
H
0.7
9.4
|
L
 -80.9%
H
0.7
84
|
L
 -99.6%
H
0.7
1734.6
|
| Eledon Pharma Inc |
|
229.3
|
2.9
|
L
 1.1%
H
2.9
3.1
|
L
 7.1%
H
2.7
3.1
|
L
 31.5%
H
2.1
3.2
|
L
 75.6%
H
1.4
3.2
|
L
 -16.3%
H
1.4
4.6
|
L
 22.6%
H
1.1
5.4
|
L
 -80.1%
H
1.1
14.8
|
L
 -99.7%
H
1.1
1425.6
|
| Enanta Pharma Inc |
|
363.0
|
12.5
|
L
 -3.8%
H
12.4
13.2
|
L
 -1.5%
H
12.4
13.7
|
L
 -7.4%
H
12.4
15.7
|
L
 -18.7%
H
12.1
17.2
|
L
 94.3%
H
4.1
17.2
|
L
 -70.0%
H
4.1
43.1
|
L
 -76.0%
H
4.1
102
|
L
 -53.8%
H
4.1
127.8
|
| Entera Bio Ltd |
|
50.9
|
1.1
|
L
 -6.7%
H
1.1
1.3
|
L
 -12.6%
H
1.1
1.5
|
L
 -24.5%
H
1.1
1.7
|
L
 -37.3%
H
1
2.0
|
L
 -42.5%
H
1
3.2
|
L
 4.7%
H
0.5
3.4
|
L
 -75.7%
H
0.5
8.7
|
L
H
0.5
10.2
|
| Evolus Inc |
|
301.9
|
4.6
|
L
 -4.5%
H
4.6
4.9
|
L
 -7.4%
H
4.6
5.2
|
L
 6.2%
H
4.1
6.3
|
L
 -34.4%
H
4.1
7.3
|
L
 -65.0%
H
4.1
13.3
|
L
 -44.8%
H
4.1
17.8
|
L
 -66.6%
H
4.1
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
4,537.7
|
14.6
|
L
 -4.3%
H
14.6
15.5
|
L
 7.2%
H
12.9
15.5
|
L
 16.4%
H
12.7
16.4
|
L
 323.2%
H
3.3
16.4
|
L
 886.5%
H
1.0
16.4
|
L
 380.3%
H
1.0
16.4
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
654.9
|
2.6
|
L
 -1.9%
H
2.5
2.6
|
L
 4.5%
H
2.4
2.8
|
L
 -26.7%
H
2.4
3.5
|
L
 -35.1%
H
2.4
4.2
|
L
 57.4%
H
0.7
4.2
|
L
 65.6%
H
0.7
4.2
|
L
 -91.3%
H
0.7
30.5
|
L
 -83.5%
H
0.7
82.7
|
| Eton Pharma Inc |
|
598.6
|
22.3
|
L
 7.5%
H
20.4
23.0
|
L
 17.9%
H
18.6
23.0
|
L
 24.5%
H
16.1
23.0
|
L
 36.4%
H
14.3
23.0
|
L
 51.0%
H
11.1
23
|
L
 466.5%
H
2.4
23
|
L
 179.3%
H
2.0
23
|
L
H
2.0
23
|
| Exelixis Inc |
|
10,718.2
|
41.3
|
L
 0.0%
H
40.9
41.7
|
L
 0.1%
H
40.9
42.1
|
L
 -5.4%
H
39.7
45.9
|
L
 -6.8%
H
39.7
47.2
|
L
 11%
H
32.4
49.6
|
L
 125.2%
H
17.9
49.6
|
L
 76.4%
H
14.9
49.6
|
L
 966.4%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
27.7
|
3.3
|
L
 -10.2%
H
3.3
3.7
|
L
 -8.4%
H
3.3
4.0
|
L
 -0.6%
H
2.8
4.0
|
L
 -10.9%
H
2.8
4.5
|
L
 127.1%
H
0.9
17.2
|
L
 -98.6%
H
0.0
468
|
L
 -99.4%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,103.8
|
13.2
|
L
 -4.1%
H
13.1
13.9
|
L
 0.2%
H
13.0
14.1
|
L
 -13.7%
H
12.9
18.9
|
L
 -24.1%
H
12.1
19
|
L
 116.9%
H
3.9
19.1
|
L
 444.4%
H
2.2
31.0
|
L
 25.4%
H
2.2
31.0
|
L
 -49.3%
H
2.2
42.5
|
| Evotec SE (ADR) |
|
863.8
|
2.4
|
L
 -0.8%
H
2.4
2.5
|
L
 5.2%
H
2.3
2.5
|
L
 -31.2%
H
2.3
3.5
|
L
 -17.6%
H
2.3
3.9
|
L
 -31.0%
H
2.3
4.8
|
L
 -74.6%
H
2.3
13.5
|
L
 -86.4%
H
2.3
26.6
|
L
 37.3%
H
1.8
26.6
|
| Fortress Biotech Inc |
|
92.8
|
3.0
|
L
 -4.8%
H
3.0
3.1
|
L
 -3.6%
H
3.0
3.2
|
L
 -11.0%
H
3.0
4.2
|
L
 -15.5%
H
2.9
4.5
|
L
 75.9%
H
1.3
4.5
|
L
 -71.9%
H
1.2
12.8
|
L
 -95.3%
H
1.2
91.5
|
L
 -93.4%
H
1.2
91.5
|
| Fennec Pharma Inc |
|
250.0
|
7.3
|
L
 -4.3%
H
7.3
7.7
|
L
 -2.7%
H
7.3
8.1
|
L
 -16.3%
H
7.3
9.2
|
L
 -4.4%
H
7.3
9.2
|
L
 10.6%
H
4.7
9.9
|
L
 -9.4%
H
4.0
11.9
|
L
 2.8%
H
3.8
11.9
|
L
 297.8%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
28.8
|
7.1
|
L
 -2.3%
H
7.1
7.4
|
L
 2.3%
H
6.7
7.5
|
L
 -14.3%
H
6.7
8.6
|
L
 -17.1%
H
6.7
9.8
|
L
 -15.3%
H
4.9
12.6
|
L
 -98.6%
H
4.5
522.5
|
L
 -99.2%
H
4.5
903.1
|
L
 -98.4%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
84.3
|
6.7
|
L
 0.2%
H
6.2
7.0
|
L
 -2.1%
H
5.5
7.0
|
L
 42.4%
H
4.2
7.8
|
L
 125.7%
H
2.9
7.8
|
L
 221.2%
H
1.3
7.8
|
L
 -59.2%
H
1.3
53.8
|
L
 -96.5%
H
1.3
200.5
|
L
H
1.3
572.4
|
| Amicus Therapeutics Inc |
|
4,531.0
|
14.4
|
L
 0.4%
H
14.4
14.4
|
L
 0.4%
H
14.4
14.4
|
L
 0.6%
H
14.3
14.4
|
L
 1.8%
H
14.2
14.4
|
L
 58.9%
H
5.5
14.4
|
L
 25.0%
H
5.5
14.6
|
L
 40.8%
H
5.5
14.6
|
L
 83.6%
H
4.4
25.4
|
| Fulcrum Therapeutics Inc |
|
450.9
|
6.8
|
L
 -3.8%
H
6.7
7.2
|
L
 -11.5%
H
6.7
8
|
L
 -38.5%
H
6.7
11.4
|
L
 -44.9%
H
6.7
12.9
|
L
 124.2%
H
2.3
15.7
|
L
 96.2%
H
2.3
15.7
|
L
 -40.4%
H
2.3
33.1
|
L
H
2.3
33.1
|
| GH Research PLC |
|
866.6
|
14.0
|
L
 -5.7%
H
13.9
14.9
|
L
 -6.6%
H
13.9
15.6
|
L
 -10.5%
H
13.9
16.5
|
L
 7.8%
H
12.2
19
|
L
 15.7%
H
8.0
19.5
|
L
 101.0%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Galmed Pharma Ltd |
|
3.9
|
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 -4.8%
H
0.6
0.7
|
L
 11.1%
H
0.5
0.7
|
L
 -29.4%
H
0.5
0.9
|
L
 -73.8%
H
0.5
2.7
|
L
 -99.2%
H
0.2
93.6
|
L
 -99.9%
H
0.2
734.4
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
1,092.8
|
18.1
|
L
 -5.5%
H
16.5
20.4
|
L
 -31.1%
H
16.5
27.2
|
L
 -39.5%
H
16.5
34.0
|
L
 -33.2%
H
16.5
38.3
|
L
 338.2%
H
2.0
38.3
|
L
 835.1%
H
0.5
38.3
|
L
 156.6%
H
0.5
38.3
|
L
H
0.5
38.3
|
| GlycoMimetics Inc |
|
703.4
|
10.9
|
L
 2.6%
H
10.6
11.1
|
L
 -2.5%
H
9.9
11.8
|
L
 -6.4%
H
9.9
13.5
|
L
 -8.0%
H
8.7
14.7
|
L
 -59.8%
H
8.7
28.8
|
L
 -92.4%
H
8.7
353
|
L
 -96.8%
H
8.7
416
|
L
 -98.2%
H
8.7
2605
|
| Genelux Corp |
|
107.3
|
2.4
|
L
 -5.5%
H
2.3
2.5
|
L
 -7.7%
H
2.3
2.8
|
L
 -9.1%
H
2.3
3.0
|
L
 -42.9%
H
2.3
5.0
|
L
 -39.7%
H
2.0
8.5
|
L
 -91.4%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
4.3
|
1.9
|
L
 -2.1%
H
1.8
2.0
|
L
 -6.5%
H
1.8
2.1
|
L
 5.6%
H
1.8
2.6
|
L
 -11.7%
H
1.7
3.6
|
L
 394.7%
H
0.1
13.0
|
L
 147.4%
H
0.1
13.0
|
L
 -63.0%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
98.6
|
0.4
|
L
 -6.7%
H
0.4
0.5
|
L
 -4.6%
H
0.4
0.5
|
L
 -80.3%
H
0.3
0.6
|
L
 -87.8%
H
0.3
3.8
|
L
 -68.9%
H
0.3
3.9
|
L
 -65.3%
H
0.3
3.9
|
L
 -95.5%
H
0.3
15.2
|
L
H
0.3
27.2
|
| GT Biopharma Inc |
|
14.5
|
0.5
|
L
 9.5%
H
0.4
0.5
|
L
 9.5%
H
0.4
0.5
|
L
H
0.4
0.5
|
L
 -39.5%
H
0.4
0.9
|
L
 -79.7%
H
0.4
3.9
|
L
 -16.4%
H
0.2
10.7
|
L
 -93.0%
H
0.2
19.7
|
L
 -100.0%
H
0.2
4845
|
| Genmab (ADR) |
|
15,409.2
|
25.1
|
L
 -2.5%
H
25.0
25.7
|
L
 -4.0%
H
25.0
26.8
|
L
 -14.3%
H
25.0
29.9
|
L
 -22.5%
H
25.0
35.4
|
L
 26.5%
H
17.2
35.4
|
L
 -30.2%
H
17.2
43
|
L
 -22.5%
H
17.2
49.1
|
L
 102.4%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
14.8
|
0.6
|
L
 1.6%
H
0.6
0.7
|
L
 -28.4%
H
0.6
0.9
|
L
 -37%
H
0.6
1.1
|
L
 -56.6%
H
0.6
1.7
|
L
 -83.9%
H
0.6
10
|
L
 -89.8%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Grifols SA (ADR) - Level III |
|
5,158.8
|
7.6
|
L
 -2.5%
H
7.5
7.8
|
L
 -2.9%
H
7.5
8.1
|
L
 -19.4%
H
7.5
9.3
|
L
 -16.0%
H
7.5
9.8
|
L
 -4.1%
H
6.2
11.1
|
L
 13.8%
H
5.3
12.2
|
L
 -52.9%
H
5.3
19.1
|
L
 -50.0%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
14.3
|
0.9
|
L
H
0.9
1.0
|
L
 -10.7%
H
0.9
1.1
|
L
 -12.4%
H
0.9
1.3
|
L
 -15.6%
H
0.8
1.3
|
L
 -14.0%
H
0.7
2.1
|
L
 -55.3%
H
0.6
4.3
|
L
 -98.3%
H
0.6
78.8
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
38.3
|
0.8
|
L
 -2.5%
H
0.8
0.8
|
L
 1.3%
H
0.8
0.9
|
L
 17.9%
H
0.5
0.9
|
L
 14.5%
H
0.5
0.9
|
L
 -27.5%
H
0.5
2.4
|
L
 -67.4%
H
0.5
8.2
|
L
H
0.5
24.0
|
L
H
0.5
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,603.3
|
27.7
|
L
 -0.3%
H
27.5
28.0
|
L
 0.4%
H
27.1
28.9
|
L
 -4.9%
H
25.9
29.4
|
L
 -26.7%
H
25.9
39.6
|
L
 -20.6%
H
25.5
40.9
|
L
 -36.9%
H
18.6
45.1
|
L
 -11.6%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,239.0
|
33.3
|
L
 -3.3%
H
33.1
34.9
|
L
 -2.4%
H
33.1
35.6
|
L
 -36%
H
33.1
54.5
|
L
 -28.3%
H
33.1
54.9
|
L
 18.5%
H
20.9
54.9
|
L
 91.8%
H
7.6
59.2
|
L
 351.6%
H
5.4
59.2
|
L
 666.8%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
2,396.3
|
13.9
|
L
 0.9%
H
13.7
14.0
|
L
 -0.3%
H
13.7
14.5
|
L
 -8.8%
H
13.1
15.2
|
L
 2.9%
H
13.1
16.3
|
L
 -13.6%
H
11.5
19.5
|
L
 3.8%
H
10.7
21.9
|
L
 -52.0%
H
7.4
43.9
|
L
 3.3%
H
7.4
43.9
|
| ImmunityBio Inc |
|
8,708.1
|
8.5
|
L
 -4.0%
H
8.4
9.3
|
L
 1.0%
H
8.0
9.3
|
L
 -2.6%
H
7.8
12.4
|
L
 307.2%
H
2.0
12.4
|
L
 208%
H
1.8
12.4
|
L
 527.4%
H
1.3
12.4
|
L
 -76.2%
H
1.2
39.6
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
2,875.9
|
32.8
|
L
 0.5%
H
32.2
33.5
|
L
 -1.0%
H
32.2
35.3
|
L
 2.4%
H
31
35.7
|
L
 -2.4%
H
29.5
39.3
|
L
 77.6%
H
13.5
39.3
|
L
 118.9%
H
13.3
47.7
|
L
 45.0%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
218.3
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 -10%
H
1.8
2.1
|
L
 2.3%
H
1.8
2.3
|
L
 4.7%
H
1.5
2.3
|
L
 -25.6%
H
1.3
2.5
|
L
 -50%
H
0.8
4.9
|
L
 -94.8%
H
0.8
41.8
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
482.4
|
9.1
|
L
 -5.9%
H
8.9
10.1
|
L
 -8.9%
H
8.9
11.6
|
L
 13.9%
H
7.8
11.6
|
L
 59.3%
H
4.2
11.6
|
L
 400.6%
H
1.3
11.6
|
L
 414.7%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immuneering Corp (Class A) |
|
324.6
|
5.0
|
L
 3.3%
H
4.8
5.0
|
L
 -0.6%
H
4.7
5.1
|
L
 0.4%
H
4.7
5.8
|
L
 -11.2%
H
4.0
8.5
|
L
 204.2%
H
1.1
10.1
|
L
 -36.1%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immunic Inc |
|
143.5
|
1.1
|
L
 -5.2%
H
1.1
1.2
|
L
 -6.0%
H
1.1
1.3
|
L
 17.0%
H
0.8
1.5
|
L
 93.0%
H
0.5
1.5
|
L
 -3.5%
H
0.5
1.5
|
L
 -34.1%
H
0.5
3.1
|
L
 -93.0%
H
0.5
17.0
|
L
 -99.7%
H
0.5
390
|
| Incyte |
|
18,066.5
|
90.8
|
L
 -2.3%
H
90.3
93.3
|
L
 -1.9%
H
90.3
94.9
|
L
 -10.4%
H
90.3
103.2
|
L
 -11.6%
H
90.3
112.3
|
L
 49.9%
H
53.6
112.3
|
L
 22.3%
H
50.3
112.3
|
L
 14.4%
H
50.3
112.3
|
L
 39.5%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
3.8
|
1.7
|
L
 -3.4%
H
1.6
1.8
|
L
 -4.0%
H
1.6
2.0
|
L
 -15.8%
H
1.6
2.2
|
L
 -16.3%
H
1.5
3.7
|
L
 123.7%
H
0.3
13.4
|
L
 1.2%
H
0.3
13.4
|
L
 -90.9%
H
0.3
28.8
|
L
 -99.5%
H
0.3
8800
|
| Indivior PLC |
|
3,664.4
|
29.3
|
L
 -3.9%
H
28.6
30.7
|
L
 -5.8%
H
28.6
32.2
|
L
 -13.5%
H
28.6
35.4
|
L
 -16.8%
H
28.6
37.7
|
L
 202.7%
H
8.6
38
|
L
 74.8%
H
7.3
38
|
L
 1593.6%
H
1.6
38
|
L
 1162.9%
H
0.4
38
|
| InMed Pharma Inc |
|
2.4
|
0.8
|
L
H
0.7
0.8
|
L
 6.5%
H
0.7
0.9
|
L
 -4.7%
H
0.7
1.0
|
L
 -31.1%
H
0.7
1.4
|
L
 -70.7%
H
0.7
8.0
|
L
 -97.2%
H
0.7
41.6
|
L
 -100.0%
H
0.7
2095
|
L
 -100.0%
H
0.7
32175
|
| Inovio Pharma Inc |
|
109.0
|
1.6
|
L
 -4.2%
H
1.6
1.7
|
L
 -4.8%
H
1.6
1.7
|
L
 -8.7%
H
1.6
2.0
|
L
 -30.7%
H
1.5
2.4
|
L
 -18.6%
H
1.3
3.0
|
L
 47.7%
H
0.3
14.8
|
L
 -84.4%
H
0.3
14.8
|
L
 -77.8%
H
0.3
33.8
|
| Insmed Inc |
|
29,315.1
|
136
|
L
 -5.6%
H
135.7
143.6
|
L
 -2.5%
H
135.7
147.4
|
L
 -17.5%
H
135.7
167
|
L
 -22.2%
H
135.7
186.2
|
L
 72.7%
H
60.4
212.8
|
L
 699.1%
H
16.0
212.8
|
L
 262.5%
H
16.0
212.8
|
L
 1046.7%
H
9.0
212.8
|
| Innoviva Inc |
|
1,607.4
|
21.7
|
L
 -1.8%
H
21.6
22.3
|
L
 -1.5%
H
21.6
22.4
|
L
 -7.2%
H
21.6
25.1
|
L
 8.6%
H
19
25.1
|
L
 26.1%
H
16.5
25.1
|
L
 93.9%
H
11.0
25.1
|
L
 77.0%
H
10.6
25.1
|
L
 77.4%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
11,727.0
|
71.0
|
L
 -0.5%
H
70.5
72.6
|
L
 -0.3%
H
70.5
73.3
|
L
 -14.6%
H
70.4
85.5
|
L
 -10.8%
H
70.4
86.7
|
L
 116.9%
H
24.0
86.7
|
L
 99.4%
H
24.0
86.7
|
L
 31.0%
H
24.0
86.7
|
L
 83.7%
H
19.6
86.7
|
| Ironwood Pharma Inc (Class A) |
|
495.7
|
3.0
|
L
 -5.9%
H
3.0
3.3
|
L
 -9.8%
H
3.0
3.5
|
L
 -23.2%
H
3.0
4.0
|
L
 -2.9%
H
3.0
5.8
|
L
 98.7%
H
0.5
5.8
|
L
 -70.9%
H
0.5
15.7
|
L
 -73.0%
H
0.5
15.7
|
L
 -64.6%
H
0.5
17.7
|
| Iterum Therapeutics PLC |
|
8.5
|
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
 -23.8%
H
0.1
0.3
|
L
 -56.8%
H
0.1
0.4
|
L
 -89.0%
H
0.1
1.5
|
L
 -85.5%
H
0.1
3.0
|
L
 -99.4%
H
0.1
37.8
|
L
H
0.1
195
|
| I-Mab (ADR) |
|
295.1
|
2.6
|
L
 -4.8%
H
2.5
2.8
|
L
 -9.5%
H
2.5
3.1
|
L
 -22.2%
H
2.5
3.9
|
L
 -38.9%
H
2.5
5.2
|
L
 197.7%
H
0.6
6.8
|
L
 -28.1%
H
0.6
6.8
|
L
 -95.2%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immuron Ltd (ADR) |
|
5.7
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 -10.3%
H
0.7
0.8
|
L
 -2.8%
H
0.7
0.9
|
L
 -25.5%
H
0.7
1.3
|
L
 -61.3%
H
0.7
2.4
|
L
 -63.0%
H
0.7
6.0
|
L
 -89.1%
H
0.7
6.7
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
109.7
|
1.2
|
L
 -7.9%
H
1.2
1.3
|
L
 -22%
H
1.2
1.5
|
L
 -27.8%
H
1.2
1.8
|
L
 -33.1%
H
1.2
1.9
|
L
 -41.5%
H
1.2
2.6
|
L
 -61.3%
H
1.2
3.6
|
L
 -74%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Jaguar Health Inc |
|
4.7
|
0.4
|
L
H
0.4
0.4
|
L
 -16%
H
0.4
0.5
|
L
 -31.2%
H
0.4
1.0
|
L
 -64.1%
H
0.4
1.9
|
L
 -93.3%
H
0.4
15.5
|
L
 -99.1%
H
0.4
76.2
|
L
 -100.0%
H
0.4
30780
|
L
 -100.0%
H
0.4
999999
|
| Jazz Pharma PLC |
|
11,119.0
|
180.6
|
L
 -0.7%
H
179.2
184
|
L
 1.2%
H
178.3
184.7
|
L
 4.9%
H
169.4
198
|
L
 8.2%
H
157.0
198
|
L
 28.5%
H
95.5
198
|
L
 30.9%
H
95.5
198
|
L
 4.8%
H
95.5
198
|
L
 52.7%
H
86.9
198
|
| Kala Pharma Inc |
|
218.7
|
0.2
|
L
 -4%
H
0.2
0.3
|
L
 -14.3%
H
0.2
0.3
|
L
 -36.8%
H
0.2
0.5
|
L
 -61.3%
H
0.2
0.7
|
L
 -96.5%
H
0.2
20.6
|
L
 -98.1%
H
0.2
20.6
|
L
 -99.9%
H
0.2
419.2
|
L
H
0.2
1337.5
|
| KalVista Pharma Inc |
|
859.3
|
17
|
L
 3.5%
H
16.3
17.2
|
L
 0.4%
H
15.1
17.4
|
L
 7.4%
H
15.1
18.7
|
L
 11.6%
H
14.2
19
|
L
 41.7%
H
9.2
19
|
L
 142.2%
H
6.3
19
|
L
 -47.5%
H
4.1
33.4
|
L
 73.6%
H
4.1
45
|
| Kiniksa Pharma Ltd (Class A) |
|
3,526.8
|
46.1
|
L
 1.0%
H
44.6
46.3
|
L
 0.7%
H
44.4
47.8
|
L
 -3.5%
H
41.1
49.1
|
L
 6.7%
H
37.0
49.1
|
L
 93.5%
H
18.3
49.1
|
L
 314.4%
H
10.3
49.1
|
L
 128.8%
H
7.4
49.1
|
L
H
5.0
49.1
|
| Kiora Pharma Inc |
|
7.7
|
2.1
|
L
 3.0%
H
2
2.1
|
L
H
2.0
2.1
|
L
 5.6%
H
1.9
2.2
|
L
 -3.2%
H
1.9
2.5
|
L
 -34.3%
H
1.8
4.2
|
L
 -38.0%
H
0.4
5.6
|
L
 -99.1%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2400
|
| Karyopharm Therapeutics Inc |
|
140.0
|
7.6
|
L
 -1.3%
H
7.4
9.0
|
L
 -2.8%
H
7.4
9.0
|
L
 -21.1%
H
7.3
11.0
|
L
 9.9%
H
5.9
11.0
|
L
 24.3%
H
3.5
11.0
|
L
 -85.6%
H
0.6
73.1
|
L
 -95.8%
H
0.6
221.0
|
L
 -93.9%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
216.1
|
11.0
|
L
 -1.4%
H
10.7
11.4
|
L
 -0.5%
H
10.6
11.4
|
L
 -32.4%
H
10.5
16.1
|
L
 -45.9%
H
10.5
21.8
|
L
 -4.2%
H
9.1
22.6
|
L
 -74.7%
H
9.1
73
|
L
 -81.5%
H
9.1
73
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
18.5
|
0.8
|
L
 2.6%
H
0.8
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
H
0.7
0.9
|
L
 -31.0%
H
0.7
1.3
|
L
 -32.2%
H
0.3
3.8
|
L
 90.5%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kazia Therapeutics Ltd (ADR) |
|
84.8
|
7.5
|
L
 -5.4%
H
7.3
8.0
|
L
 -0.1%
H
7.0
8.5
|
L
 21.8%
H
5.6
10.5
|
L
 -31.2%
H
4.9
11.1
|
L
 53.3%
H
2.9
17.4
|
L
 -84.1%
H
2.9
84
|
L
 -98.7%
H
2.9
744.5
|
L
 -98.3%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
17.7
|
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 1.4%
H
0.7
0.8
|
L
 9.2%
H
0.6
0.9
|
L
 22.4%
H
0.5
0.9
|
L
 -55.1%
H
0.5
1.9
|
L
 -71.9%
H
0.5
6.9
|
L
 -88.2%
H
0.5
12.5
|
L
 -81.8%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
150.7
|
4.0
|
L
 -1.0%
H
3.9
4.1
|
L
 -38.5%
H
3.9
6.5
|
L
 -43.6%
H
3.9
7.5
|
L
 -50%
H
3.9
9.0
|
L
 -38.9%
H
3.9
9.0
|
L
 29.7%
H
2.7
11.5
|
L
 -64.8%
H
1.5
12.9
|
L
 -61.4%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
4,084.1
|
204.8
|
L
 -2.7%
H
204.0
214.3
|
L
 0.9%
H
201.9
214.5
|
L
 11.3%
H
178.7
227.9
|
L
 2.2%
H
175.9
227.9
|
L
 87.2%
H
93.6
227.9
|
L
 185.7%
H
49.3
227.9
|
L
 98.4%
H
46.8
227.9
|
L
 220.7%
H
36.9
227.9
|
| Atyr Pharma Inc |
|
79.4
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -4.7%
H
0.8
0.9
|
L
 -22.1%
H
0.8
1.1
|
L
 8%
H
0.7
1.1
|
L
 -78.5%
H
0.6
7.3
|
L
 -57.8%
H
0.6
7.3
|
L
 -85.6%
H
0.6
13.1
|
L
 -98.9%
H
0.6
90.9
|
| Lipocine Inc |
|
52.2
|
7.2
|
L
 -2.2%
H
6.9
7.3
|
L
 -2.6%
H
6.9
8
|
L
 -27.0%
H
6.9
10.5
|
L
 68.2%
H
4.1
12.4
|
L
 104.3%
H
2.5
12.4
|
L
 29.3%
H
2.3
12.4
|
L
 -74.8%
H
2.3
32.1
|
L
 -95.8%
H
2.3
215.2
|
| Liquidia Corp |
|
3,208.2
|
36.4
|
L
 -2.5%
H
36.2
37.6
|
L
 -0.7%
H
35.1
37.6
|
L
 8.4%
H
29.1
39.6
|
L
 5.4%
H
29.1
46.7
|
L
 135.8%
H
11.3
46.7
|
L
 412.8%
H
5.7
46.7
|
L
 1214.4%
H
2.3
46.7
|
L
H
2.3
46.7
|
| Lisata Therapeutics Inc |
|
45.3
|
5.0
|
L
 -0.2%
H
5
5.0
|
L
 -0.4%
H
5
5.1
|
L
 11.8%
H
4.0
5.1
|
L
 143.2%
H
1.8
5.1
|
L
 119.7%
H
1.8
5.1
|
L
 53.7%
H
1.8
5.1
|
L
 -84.4%
H
1.8
32.1
|
L
 -95.9%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
23.8
|
2.1
|
L
 -1.4%
H
2.0
2.2
|
L
 -10.9%
H
2.0
2.6
|
L
 -18.4%
H
2.0
3.1
|
L
 -34.7%
H
2.0
3.7
|
L
 -42.7%
H
2.0
5.7
|
L
 -54.2%
H
2.0
12.0
|
L
 -90.0%
H
2.0
21.8
|
L
H
2.0
24.8
|
| Lexicon Pharma Inc |
|
660.9
|
1.6
|
L
 -3.7%
H
1.5
1.6
|
L
 -7.7%
H
1.5
1.7
|
L
 6.1%
H
1.4
1.8
|
L
 33.3%
H
1.1
1.8
|
L
 358.8%
H
0.3
1.8
|
L
 -31.0%
H
0.3
3.8
|
L
 -76.7%
H
0.3
6.8
|
L
 -87.2%
H
0.3
19.6
|
| Legend Biotech Corp (ADR) |
|
3,220.1
|
17.4
|
L
 -2.6%
H
17.4
18.8
|
L
 -7.2%
H
17.4
19.3
|
L
 -3.9%
H
17.4
21.6
|
L
 -20.6%
H
16.2
24.1
|
L
 -53.8%
H
16.2
45.3
|
L
 -62.3%
H
16.2
77.3
|
L
 -34.3%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
6.2
|
0.9
|
L
H
0.8
0.9
|
L
 -9.6%
H
0.8
1.0
|
L
 -15%
H
0.8
1.0
|
L
 -22.0%
H
0.5
1.2
|
L
 -41.0%
H
0.5
7
|
L
 -99.7%
H
0.1
408.5
|
L
 -100.0%
H
0.1
3045
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
10.2
|
2.1
|
L
H
2.0
2.1
|
L
 1.0%
H
2.0
2.2
|
L
 -16.3%
H
1.8
2.7
|
L
 -47.2%
H
1.8
5.3
|
L
 -92.4%
H
1.8
33
|
L
 -99.4%
H
1.8
3318.8
|
L
 -99.9%
H
1.8
3318.8
|
L
H
1.8
21555
|
| Madrigal Pharma Inc |
|
10,120.2
|
441.2
|
L
 -2.9%
H
438.9
466.9
|
L
 -0.8%
H
427.8
466.9
|
L
 1.4%
H
416.2
466.9
|
L
 -25.4%
H
416.2
615
|
L
 31.6%
H
265
615
|
L
 72.4%
H
119.8
615
|
L
 276.8%
H
52.3
615
|
L
 5373.4%
H
6.6
615
|
| MediWound Ltd |
|
217.9
|
17.0
|
L
 -0.1%
H
16.7
17.3
|
L
 2.3%
H
16.7
17.6
|
L
 -5.1%
H
16.4
18.3
|
L
 -9.6%
H
16.3
19.7
|
L
 -0.5%
H
14.1
22.5
|
L
 55.3%
H
7.1
24
|
L
 -56.2%
H
7.1
43.5
|
L
 -69.1%
H
7.1
62.3
|
| MEI Pharma Inc |
|
42.5
|
1.2
|
L
H
1.2
1.2
|
L
 -0.9%
H
1.2
1.3
|
L
 5.4%
H
1.0
1.3
|
L
 -18.2%
H
1.0
1.7
|
L
 -49.4%
H
1.0
9
|
L
 -75.7%
H
1.0
9
|
L
 -98.5%
H
1.0
78.2
|
L
 -95.1%
H
1.0
102.8
|
| Macrogenics Inc |
|
181.8
|
2.9
|
L
 -1.4%
H
2.8
2.9
|
L
 -4.7%
H
2.8
3.2
|
L
 68.2%
H
1.6
3.5
|
L
 90.7%
H
1.5
3.5
|
L
 36.2%
H
1.0
3.5
|
L
 -57.2%
H
1.0
21.9
|
L
 -90.6%
H
1.0
36.5
|
L
 -82.3%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
2.6
|
0.2
|
L
 -55.6%
H
0.2
0.4
|
L
 -57.9%
H
0.2
0.4
|
L
 -69.8%
H
0.2
0.6
|
L
 -77.5%
H
0.2
1.0
|
L
 -96.3%
H
0.2
5.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
77.8
|
L
 -2.8%
H
75.8
82.5
|
L
 -0.1%
H
75.8
82.5
|
L
 56.9%
H
48.9
88.0
|
L
 83.2%
H
35.8
88.0
|
L
 294.9%
H
16.6
88.0
|
L
 539.5%
H
9.1
88.0
|
L
 -61.0%
H
5.1
227.2
|
L
H
5.1
336
|
| Mirum Pharma Inc |
|
5,340.8
|
88.5
|
L
 -2.4%
H
86.9
91.7
|
L
 -2.4%
H
86.9
96.7
|
L
 -15.8%
H
84.3
109.3
|
L
 13.9%
H
73.8
109.3
|
L
 84.9%
H
36.9
109.3
|
L
 275.0%
H
21.8
109.3
|
L
 350.7%
H
12.8
109.3
|
L
H
6.5
109.3
|
| Milestone Pharma Inc |
|
115.8
|
1.4
|
L
 -20%
H
1.4
1.6
|
L
 -20%
H
1.4
1.8
|
L
 -20%
H
1.4
1.8
|
L
 -36.7%
H
1.4
2.3
|
L
 -30.3%
H
0.6
3.1
|
L
 -59.0%
H
0.6
4.5
|
L
 -80.7%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,167.0
|
16.3
|
L
 -2.5%
H
16.0
16.9
|
L
 -5.0%
H
16.0
17.5
|
L
 -13.3%
H
16.0
19.5
|
L
 21.5%
H
11.1
19.5
|
L
 -60.0%
H
6.0
62.8
|
L
 -23.7%
H
6.0
65.0
|
L
 58.0%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
761.0
|
2.5
|
L
 -2.0%
H
2.4
2.5
|
L
 -10.8%
H
2.4
2.9
|
L
 -55.4%
H
2.4
5.7
|
L
 -57.7%
H
2.4
6.5
|
L
 -53.0%
H
2.4
6.5
|
L
 -39.3%
H
2.4
7.6
|
L
 -33.6%
H
2.4
7.6
|
L
 -75.3%
H
0.7
11.2
|
| Mind Medicine Inc |
|
1,834.4
|
18.4
|
L
 -1.4%
H
18.2
19.7
|
L
 1.9%
H
17.3
19.7
|
L
 7.4%
H
16.5
19.7
|
L
 44.9%
H
12.6
19.7
|
L
 176.7%
H
4.7
19.7
|
L
 536.7%
H
2.4
19.7
|
L
 -56.0%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
76.8
|
1.6
|
L
 12.2%
H
1.4
1.6
|
L
 15.6%
H
1.4
1.6
|
L
 4%
H
1.3
1.6
|
L
 9.1%
H
1.2
1.9
|
L
 3.3%
H
1.1
2.0
|
L
 -24.6%
H
1.1
2.7
|
L
 -73.1%
H
1.1
5.8
|
L
 -73.3%
H
1.1
14.5
|
| TNF Pharma Inc |
|
28.8
|
3.7
|
L
 -6.9%
H
3.5
4.0
|
L
 -4.7%
H
3.5
4.6
|
L
 4.3%
H
3.4
5.0
|
L
 -24.8%
H
3.4
6.3
|
L
 -90.0%
H
2.5
44.4
|
L
 -99.9%
H
2.5
7050
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| NewAmsterdam Pharma Co NV |
|
3,327.4
|
28.9
|
L
 -5.0%
H
28.9
31.4
|
L
 1.1%
H
28.7
31.4
|
L
 -18.7%
H
28.5
36.9
|
L
 -17.6%
H
28.5
37.8
|
L
 20.2%
H
14.1
42
|
L
 129.1%
H
5.6
42
|
L
 189.1%
H
5.6
42
|
L
H
5.6
42
|
| Neurocrine Biosciences Inc |
|
12,814.4
|
127.7
|
L
 -1.6%
H
126.7
130.2
|
L
 -1.6%
H
126.7
132.3
|
L
 -0.7%
H
126.6
134.8
|
L
 -11.9%
H
122.1
148.6
|
L
 16%
H
84.2
160.2
|
L
 31.3%
H
84.2
160.2
|
L
 38.5%
H
71.9
160.2
|
L
 264.2%
H
33.6
160.2
|
| Minerva Neurosciences Inc |
|
326.3
|
7.5
|
L
 -6.6%
H
7.5
8.2
|
L
 -3.7%
H
7.5
8.8
|
L
 19.5%
H
5.0
8.8
|
L
 86.6%
H
3.8
8.8
|
L
 335.8%
H
1.2
12.5
|
L
 374.2%
H
1.2
13.5
|
L
 -69.1%
H
1.2
28.3
|
L
 -83.7%
H
1.2
126.7
|
| Nektar Therapeutics |
|
2,071.8
|
72.2
|
L
 -3.5%
H
70.8
75.5
|
L
 -1.4%
H
70.8
76.7
|
L
 -2.1%
H
62.5
77
|
L
 54.2%
H
33.4
77
|
L
 451.3%
H
6.5
77
|
L
 417.7%
H
6.2
77
|
L
 -77.8%
H
6.2
339.3
|
L
 -61.8%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
10.8
|
2.4
|
L
 -3.3%
H
2.4
2.5
|
L
 -13.5%
H
2.4
2.8
|
L
 -12.2%
H
2.4
3.1
|
L
 -8.9%
H
1.9
3.3
|
L
 -84.2%
H
1.9
30.8
|
L
 -99.6%
H
1.2
640
|
L
 -99.9%
H
1.2
1772
|
L
H
1.2
2940
|
| Nurix Therapeutics Inc |
|
1,484.0
|
14.4
|
L
 -3.3%
H
14.4
15.5
|
L
 -4.1%
H
14.4
15.7
|
L
 -8.6%
H
14.4
16.5
|
L
 -22.1%
H
14.4
20.2
|
L
 4.0%
H
8.2
22.5
|
L
 51.6%
H
4.2
29.6
|
L
 -56.4%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
25.0
|
0.8
|
L
 -5.1%
H
0.8
0.8
|
L
 -12.8%
H
0.8
1.1
|
L
 -16.7%
H
0.8
1.1
|
L
 -7.4%
H
0.7
1.1
|
L
 -29.9%
H
0.7
2.6
|
L
 -58.8%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
59.0
|
1.9
|
L
 0.5%
H
1.8
1.9
|
L
 -0.5%
H
1.8
2.2
|
L
 0.5%
H
1.6
2.2
|
L
 -21.9%
H
1.6
2.8
|
L
 -10.6%
H
1.6
3.8
|
L
 -73.6%
H
1.1
54
|
L
 -99.4%
H
1.1
570
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
218.0
|
8.2
|
L
 1.9%
H
7.8
8.3
|
L
 -8.9%
H
7.8
9.3
|
L
 -2.7%
H
7.8
9.9
|
L
 5.8%
H
7.2
9.9
|
L
 -12.0%
H
5.6
11.5
|
L
 -33.9%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
35.6
|
10.0
|
L
 -0.9%
H
9.6
10.4
|
L
 -21.2%
H
9.6
13
|
L
 -27.2%
H
9.6
14.5
|
L
 -12.2%
H
9.6
14.7
|
L
 35.6%
H
2.8
15.7
|
L
 -48.6%
H
2.8
30.8
|
L
 -93.0%
H
2.8
146.0
|
L
H
2.8
1308
|
| Ocugen Inc |
|
668.9
|
2.0
|
L
 -8.9%
H
2.0
2.3
|
L
 -17.7%
H
2.0
2.7
|
L
 27.5%
H
1.5
2.7
|
L
 45.7%
H
1.3
2.7
|
L
 251.7%
H
0.6
2.7
|
L
 114.7%
H
0.3
2.7
|
L
 -77.1%
H
0.3
17.7
|
L
 -98.6%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,441.5
|
24.9
|
L
 -2.0%
H
24.5
26.0
|
L
 -2.2%
H
24.5
27.1
|
L
 -14.8%
H
24.5
30.7
|
L
 17.0%
H
19.6
30.7
|
L
 26.6%
H
14
30.7
|
L
 220.8%
H
6.3
30.7
|
L
H
6.3
30.7
|
L
H
6.3
30.7
|
| Ocular Therapeutix Inc |
|
1,780.7
|
8.2
|
L
 -1.1%
H
8.0
8.4
|
L
 -6.6%
H
8.0
9.0
|
L
 5.1%
H
7.7
11.5
|
L
 -34.9%
H
6.2
13.1
|
L
 10.0%
H
5.8
16.4
|
L
 68.3%
H
2
16.4
|
L
 -60.4%
H
2
21.2
|
L
 -9.5%
H
2
24.3
|
| Opus Genetics Inc |
|
312.3
|
4.4
|
L
 -4.2%
H
4.3
4.7
|
L
 -12.7%
H
4.3
5.3
|
L
 29.5%
H
3.3
5.3
|
L
 119.5%
H
1.9
5.3
|
L
 281.7%
H
0.7
5.3
|
L
 17.7%
H
0.7
6.6
|
L
 -39.4%
H
0.7
7.3
|
L
 -97.1%
H
0.7
340.8
|
| Olema Pharma Inc |
|
1,227.2
|
14.1
|
L
 -5.9%
H
14.0
15.0
|
L
 -4.3%
H
14.0
16.8
|
L
 -41.5%
H
13.0
25.3
|
L
 -49.6%
H
13.0
29.5
|
L
 241.8%
H
2.9
36.3
|
L
 290.0%
H
2.9
36.3
|
L
 -68.2%
H
2
43.9
|
L
H
2
60.3
|
| Omeros Corp |
|
779.9
|
11
|
L
 -1.1%
H
10.9
11.2
|
L
 -1.7%
H
10.7
11.4
|
L
 -8.6%
H
10.7
12.1
|
L
 14.6%
H
8.6
17.7
|
L
 20.9%
H
3.0
17.7
|
L
 238.5%
H
0.9
17.7
|
L
 -44.8%
H
0.9
20.5
|
L
 -26.3%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
1,250.0
|
11.2
|
L
 0.5%
H
10.8
11.4
|
L
 -6.2%
H
10.6
12.5
|
L
 0.5%
H
10.6
14.3
|
L
 38.8%
H
7.8
14.3
|
L
 48.6%
H
3.9
14.9
|
L
 148.6%
H
3.9
16.7
|
L
 -57.8%
H
2.4
27.1
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
138.9
|
3.5
|
L
 -3.3%
H
3.5
3.6
|
L
 1.8%
H
3.4
3.7
|
L
 8.4%
H
3.2
3.8
|
L
 19.1%
H
2.8
3.8
|
L
 47.3%
H
1.8
3.8
|
L
 59.4%
H
1.7
5.3
|
L
 -61.9%
H
1.7
31.5
|
L
 -43.4%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
29.1
|
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 -10.3%
H
0.3
0.4
|
L
 -14.6%
H
0.3
0.5
|
L
 -82.6%
H
0.3
2.1
|
L
 -76.4%
H
0.3
3.0
|
L
 -99.9%
H
0.3
812
|
L
 -100.0%
H
0.3
1308
|
L
H
0.3
17568
|
| Ovid Therapeutics Inc |
|
186.6
|
2.6
|
L
 13.9%
H
2.4
2.7
|
L
 33.0%
H
1.9
2.7
|
L
 78.2%
H
1.4
2.7
|
L
 78.2%
H
1.4
2.7
|
L
 509.3%
H
0.2
2.7
|
L
 14.4%
H
0.2
4.1
|
L
 -41.4%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
2,057.5
|
50.8
|
L
 -3.1%
H
49.9
52.6
|
L
 2.6%
H
49.9
54.2
|
L
 -3.9%
H
45.2
56.0
|
L
 36.3%
H
36.5
56.3
|
L
 132.7%
H
16.2
56.3
|
L
 241.4%
H
9.4
56.3
|
L
 101.2%
H
9.4
56.3
|
L
 96.6%
H
9.4
56.3
|
| Palisade Bio Inc |
|
282.0
|
1.9
|
L
 -5.0%
H
1.9
2.0
|
L
 -2.6%
H
1.9
2.1
|
L
 18.1%
H
1.6
2.1
|
L
 3.3%
H
1.5
2.6
|
L
 142.3%
H
0.5
2.6
|
L
 -92.7%
H
0.4
54.8
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
1041300
|
| Puma biotech Inc |
|
311.4
|
6.1
|
L
 -0.5%
H
6.1
6.2
|
L
 3.7%
H
6.0
6.3
|
L
 -10.4%
H
5.5
7.7
|
L
 8.7%
H
5.5
7.7
|
L
 79.5%
H
2.6
7.7
|
L
 147.8%
H
2.1
7.7
|
L
 -44.1%
H
1.6
12.0
|
L
 -84.5%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
895.2
|
22.1
|
L
 -2.0%
H
21.8
22.8
|
L
 -4.9%
H
21.2
24.1
|
L
 -4.8%
H
20.6
24.1
|
L
 -16.1%
H
18.8
27.0
|
L
 -7.2%
H
18.8
27.6
|
L
 -44.3%
H
11.2
48.6
|
L
 -68.4%
H
11.2
82.2
|
L
 -53.8%
H
11.2
82.2
|
| Processa Pharma Inc |
|
5.3
|
2.3
|
L
 -0.4%
H
2.1
2.5
|
L
 -21.4%
H
2.1
3.3
|
L
 10.5%
H
1.8
3.3
|
L
 -38.6%
H
1.8
4.3
|
L
 -78.2%
H
1.8
19.6
|
L
 -98.9%
H
1.8
450
|
L
 -100.0%
H
1.8
6694.5
|
L
 -99.9%
H
1.8
17937.5
|
| PDS biotech Corp |
|
31.2
|
0.6
|
L
 -8.1%
H
0.5
0.7
|
L
 -9.5%
H
0.5
0.7
|
L
 -12.3%
H
0.5
0.7
|
L
 -36.0%
H
0.5
1.2
|
L
 -58.1%
H
0.5
1.9
|
L
 -90.8%
H
0.5
10.3
|
L
 -89.4%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| Phathom Pharma Inc |
|
883.3
|
11.2
|
L
 0.5%
H
11.1
11.9
|
L
 8.1%
H
10.3
11.9
|
L
 -1.8%
H
10.0
14.4
|
L
 -36.1%
H
10.0
18.3
|
L
 79.1%
H
2.2
18.3
|
L
 74.3%
H
2.2
19.7
|
L
 -74.2%
H
2.2
45.2
|
L
H
2.2
64.5
|
| Pharvaris NV |
|
1,688.9
|
26
|
L
 -0.5%
H
25.7
26.6
|
L
 2.3%
H
25.6
27.9
|
L
 -7.5%
H
25.0
29.0
|
L
 1.6%
H
23.6
29.0
|
L
 68.2%
H
11.5
29.8
|
L
 268.8%
H
6.3
33
|
L
 -21.8%
H
1.8
35.5
|
L
H
1.8
42.9
|
| Praxis Precision Medicines Inc |
|
8,308.2
|
298.3
|
L
 0.3%
H
294.6
306.6
|
L
 1.5%
H
285
313
|
L
 -11.0%
H
285
356
|
L
 9.3%
H
266.5
356
|
L
 691.5%
H
26.7
356
|
L
 1812.2%
H
11.9
356
|
L
 -41.4%
H
11.9
559.2
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
1.8
|
2.3
|
L
 -0.4%
H
2.3
2.5
|
L
 -18.0%
H
2.3
2.8
|
L
 -34.1%
H
2.3
3.4
|
L
 159.1%
H
0.6
3.7
|
L
 -17.4%
H
0.6
3.7
|
L
 -93.1%
H
0.2
158.5
|
L
 -99.2%
H
0.2
470.4
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
162.2
|
1.5
|
L
 -3.1%
H
1.5
1.7
|
L
 -15.4%
H
1.5
1.8
|
L
 6.9%
H
1.4
2.0
|
L
 -30.3%
H
1.3
2.3
|
L
 -5.5%
H
1.1
3.1
|
L
 -51.4%
H
1.1
4.6
|
L
 -72.7%
H
0.5
9.5
|
L
 -63.9%
H
0.5
24
|
| Plus Therapeutics Inc |
|
44.6
|
0.3
|
L
 4.2%
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -10.7%
H
0.2
0.4
|
L
 -56.1%
H
0.2
0.6
|
L
 -81.9%
H
0.2
1.8
|
L
 -94.0%
H
0.2
5.1
|
L
 -99.4%
H
0.2
53.1
|
L
 -100.0%
H
0.2
40500
|
| PTC Therapeutics Inc |
|
5,405.2
|
65.3
|
L
 -2.7%
H
65.1
68.2
|
L
 1.3%
H
64.7
68.9
|
L
 -7.6%
H
61.4
72.5
|
L
 -16.9%
H
61.4
80.2
|
L
 15.3%
H
36.0
87.5
|
L
 34.7%
H
17.5
87.5
|
L
 16.2%
H
17.5
87.5
|
L
 1001.2%
H
4.0
87.5
|
| Pulmatrix Inc |
|
9.1
|
2.5
|
L
 15.8%
H
2.1
2.5
|
L
 18.0%
H
2.0
2.5
|
L
 -12.3%
H
1.6
3.4
|
L
 5.1%
H
1.6
3.4
|
L
 -67.2%
H
1.6
9.4
|
L
 -17.5%
H
1.6
10.4
|
L
 -91.4%
H
1.6
30.4
|
L
 -99.6%
H
1.6
1396
|
| Polypid Ltd |
|
79.4
|
4.2
|
L
 -4.8%
H
4.2
4.3
|
L
 -0.7%
H
4.1
4.7
|
L
 -0.5%
H
4.0
4.7
|
L
 4.8%
H
3.9
5.1
|
L
 46.0%
H
2.3
5.1
|
L
 -74.0%
H
2.3
15.7
|
L
 -98.6%
H
2.3
304.9
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
91.5
|
1.5
|
L
 -4.6%
H
1.5
1.6
|
L
 -4.6%
H
1.5
1.7
|
L
 3.5%
H
1.3
1.7
|
L
 14.8%
H
1.0
2.2
|
L
 31.3%
H
0.8
5.6
|
L
 -37.7%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,070.1
|
15.4
|
L
 -0.7%
H
14.8
15.8
|
L
 5.9%
H
14.7
15.8
|
L
 -6.1%
H
14.5
17.3
|
L
 -7.6%
H
14.5
21.3
|
L
 72.2%
H
7.5
21.3
|
L
 50%
H
6.7
21.3
|
L
 15.8%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
3.6
|
4.0
|
L
 5.0%
H
3.7
4
|
L
 -2.9%
H
3.7
4.3
|
L
 -19.6%
H
3.7
5.7
|
L
 -43.8%
H
3.7
7.3
|
L
 -85.6%
H
3.7
29.4
|
L
 -100.0%
H
3.7
8640
|
L
 -100.0%
H
3.7
27000
|
L
 -100.0%
H
3.7
278000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
120.4
|
0.6
|
L
 -34.1%
H
0.6
0.9
|
L
 -40.6%
H
0.6
1.0
|
L
 -42.3%
H
0.6
1.2
|
L
 -86.2%
H
0.6
4.7
|
L
 -93.3%
H
0.6
17.2
|
L
 -92.1%
H
0.6
17.2
|
L
 -97.6%
H
0.6
27.8
|
L
H
0.6
110
|
| Quoin Pharma Ltd (ADR) |
|
12.8
|
7.9
|
L
 -3.9%
H
7.8
8.2
|
L
 -1.5%
H
7.4
8.5
|
L
 -7.8%
H
7.4
10.0
|
L
 -44.1%
H
7
14.7
|
L
 -96.1%
H
5.1
294
|
L
 -99.8%
H
5.1
8400
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Ultragenyx Pharmaceutical Inc |
|
1,920.0
|
19.9
|
L
 -2.7%
H
19.9
20.7
|
L
 -6.9%
H
19.9
22.2
|
L
 -12.5%
H
19.9
23.8
|
L
 -40.7%
H
18.4
35.1
|
L
 -48.9%
H
18.4
42.4
|
L
 -49.1%
H
18.4
60.4
|
L
 -84.1%
H
18.4
126.3
|
L
 -64.7%
H
18.4
179.7
|
| Regeneron Pharma |
|
77,478.9
|
732.9
|
L
 -0.6%
H
728.6
744.9
|
L
 -1.7%
H
727.9
771.2
|
L
 -6%
H
727.9
794.8
|
L
 -4.6%
H
718.4
821.1
|
L
 10.6%
H
476.5
821.1
|
L
 -3.5%
H
476.5
1211.2
|
L
 54.7%
H
451.6
1211.2
|
L
 101.1%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
13,534.2
|
27.4
|
L
 1.3%
H
26.3
28.7
|
L
 17.8%
H
22.3
29.5
|
L
 -6.2%
H
20
29.7
|
L
 38.2%
H
19.4
69
|
L
 2219.5%
H
0.6
83.6
|
L
 3754.9%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
6,415.0
|
113.9
|
L
 -3.2%
H
113.6
117.8
|
L
 -0.3%
H
113.5
122.6
|
L
 -16.1%
H
112.5
139.4
|
L
 -29.9%
H
112.5
175.8
|
L
 -18.3%
H
103.0
175.8
|
L
 -33.9%
H
103.0
211.1
|
L
 -44.2%
H
103.0
327.3
|
L
 372.9%
H
21.1
327.3
|
| Regenxbio Inc |
|
418.1
|
8.1
|
L
 -3.1%
H
8.1
8.5
|
L
 -5.5%
H
8.0
9
|
L
 -0.5%
H
7.8
10.8
|
L
 -44.5%
H
7.6
16.2
|
L
 -3.1%
H
5.0
16.2
|
L
 -61.2%
H
5.0
28.8
|
L
 -79.7%
H
5.0
46.5
|
L
 -30.3%
H
5.0
85.1
|
| Rigel Pharma |
|
479.6
|
26.0
|
L
 -0.5%
H
25.5
26.5
|
L
 0.0%
H
25.0
27.3
|
L
 -26.8%
H
25.0
36.7
|
L
 -37.6%
H
25.0
49.1
|
L
 27.4%
H
15.5
52.2
|
L
 1741.1%
H
0.7
52.2
|
L
 550.6%
H
0.6
52.2
|
L
 1166.3%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
445.1
|
6.1
|
L
 -2.9%
H
5.8
6.7
|
L
 2.7%
H
5.8
6.7
|
L
 47.0%
H
4.0
7.5
|
L
 39.5%
H
3.2
7.5
|
L
 1923.3%
H
0.2
7.5
|
L
 150.8%
H
0.2
7.5
|
L
 -83.4%
H
0.2
40
|
L
 10.0%
H
0.2
54
|
| RenovoRx Inc |
|
36.6
|
1
|
L
 -1.0%
H
1.0
1.0
|
L
 19.1%
H
0.8
1.1
|
L
 9.9%
H
0.8
1.1
|
L
 7.5%
H
0.8
1.3
|
L
 1.0%
H
0.7
1.5
|
L
 -66.4%
H
0.6
4.6
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
19,824.9
|
27.7
|
L
 -0.4%
H
27.1
28.0
|
L
 -1.3%
H
27.1
29.0
|
L
 2.0%
H
26.9
30.3
|
L
 23.6%
H
20.8
30.3
|
L
 152.5%
H
8.7
30.3
|
L
 218.0%
H
6.6
30.3
|
L
 183.5%
H
2.5
30.3
|
L
H
2.5
30.3
|
| Royalty Pharma PLC (Class A) |
|
19,433.1
|
45.4
|
L
 -0.4%
H
44.7
46.1
|
L
 -0.6%
H
44.7
46.4
|
L
 0.5%
H
44.7
47.9
|
L
 17.5%
H
38.3
47.9
|
L
 35.4%
H
29.7
47.9
|
L
 28.2%
H
24.1
47.9
|
L
 -3.1%
H
24.1
47.9
|
L
H
24.1
56.5
|
| Reviva Pharma Holdings Inc |
|
4.7
|
0.8
|
L
 -3.6%
H
0.8
0.9
|
L
 -67.6%
H
0.7
2.7
|
L
 -83.8%
H
0.7
5.1
|
L
 -93.3%
H
0.7
12.5
|
L
 -96.4%
H
0.7
23.4
|
L
 -99.0%
H
0.7
185
|
L
 -99.5%
H
0.7
190
|
L
H
0.7
302
|
| Rezolute Inc |
|
238.3
|
2.5
|
L
 0.8%
H
2.4
2.5
|
L
 -4.2%
H
2.3
2.7
|
L
 -24.3%
H
2.3
3.7
|
L
 40.7%
H
1.8
4.1
|
L
 -19.4%
H
1.1
11.5
|
L
 23.9%
H
0.7
11.5
|
L
 -68.1%
H
0.7
17.4
|
L
 -95.0%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.5
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -10.2%
H
0.8
1.1
|
L
 -25.4%
H
0.8
1.4
|
L
 -68.6%
H
0.8
3.3
|
L
 -99.4%
H
0.8
145
|
L
 -100.0%
H
0.8
11180
|
L
 -100.0%
H
0.8
16540
|
| Sunshine Biopharma Inc |
|
5.1
|
1.0
|
L
 -4.6%
H
1.0
1.1
|
L
 -5.5%
H
1.0
1.2
|
L
 -11.9%
H
1.0
1.3
|
L
 -25.2%
H
1.0
1.4
|
L
 -53.4%
H
1.0
3.9
|
L
 -98.7%
H
0.1
140
|
L
 -100.0%
H
0.1
6280
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
52.9
|
7.5
|
L
 -3.6%
H
7.3
7.9
|
L
 -9.2%
H
7.3
8.7
|
L
 -7.4%
H
7.3
9.8
|
L
 -47.6%
H
7.3
14.8
|
L
 2585.7%
H
0.2
34.3
|
L
 -5.3%
H
0.2
34.3
|
L
 -24.0%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
41.5
|
0.9
|
L
 4.5%
H
0.9
0.9
|
L
 8.1%
H
0.9
1.0
|
L
 19.2%
H
0.7
1.0
|
L
 47.6%
H
0.6
1.0
|
L
 -10.6%
H
0.6
1.3
|
L
 -19.1%
H
0.6
3.9
|
L
 -88.9%
H
0.6
10.3
|
L
 -97.8%
H
0.6
55.1
|
| Shuttle Pharma Holdings Inc |
|
5.0
|
0.9
|
L
 -6.3%
H
0.9
1.0
|
L
 -5.3%
H
0.9
1.1
|
L
 -16.0%
H
0.8
1.1
|
L
 -48.3%
H
0.8
4.4
|
L
 -91.2%
H
0.8
13.6
|
L
 -99.7%
H
0.8
550
|
L
H
0.8
25252
|
L
H
0.8
25252
|
| SIGA Tech Inc |
|
353.9
|
4.9
|
L
 -2.8%
H
4.9
5.1
|
L
 -6.1%
H
4.8
5.5
|
L
 -26.8%
H
4.8
6.9
|
L
 -21.2%
H
4.8
7.1
|
L
 -12.4%
H
4.8
9.6
|
L
 -10.7%
H
4.2
12.8
|
L
 -27.6%
H
4.2
27.0
|
L
 798.2%
H
0.4
27.0
|
| SILO Pharma Inc |
|
5.1
|
0.4
|
L
 9.1%
H
0.3
0.4
|
L
 12.5%
H
0.3
0.4
|
L
 24.1%
H
0.3
0.4
|
L
 -5.3%
H
0.2
0.4
|
L
 -73.7%
H
0.2
1.4
|
L
 -81.0%
H
0.2
4.5
|
L
 -97.8%
H
0.2
496
|
L
 -99.3%
H
0.2
496
|
| Sol-Gel Tech Ltd |
|
203.3
|
73.0
|
L
 -10.7%
H
72
78.9
|
L
 -13.1%
H
72
88.5
|
L
 -13.1%
H
68
98.0
|
L
 73.1%
H
40.1
98.0
|
L
 12481.0%
H
0.4
98.0
|
L
 2015.1%
H
0.3
98.0
|
L
 457.4%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Soleno Therapeutics Inc |
|
1,715.0
|
33.2
|
L
 -1.2%
H
32.6
33.8
|
L
 -1.6%
H
32.2
34.9
|
L
 -15.6%
H
32.2
41.9
|
L
 -30.6%
H
32.2
50.9
|
L
 -31.4%
H
32.2
90.3
|
L
 1544.6%
H
2.0
90.3
|
L
 39.3%
H
0.9
90.3
|
L
 -67.9%
H
0.9
117.8
|
| SELLAS Life Sciences Grp Inc |
|
854.6
|
4.8
|
L
 -8.5%
H
4.8
5.6
|
L
 -11.4%
H
4.7
5.7
|
L
 14.7%
H
4.3
6.1
|
L
 101.7%
H
2.4
6.1
|
L
 293.4%
H
1.0
6.1
|
L
 271.9%
H
0.5
6.1
|
L
 -55.2%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Soligenix Inc |
|
12.1
|
1.2
|
L
 -1.6%
H
1.2
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 9.1%
H
1.1
1.3
|
L
 -13.0%
H
1.0
1.5
|
L
 -49.6%
H
1.0
6.2
|
L
 -96.5%
H
1.0
85.3
|
L
 -99.7%
H
1.0
432
|
L
 -99.9%
H
1.0
2160
|
| Sonoma Pharma Inc |
|
4.2
|
2.4
|
L
 -0.4%
H
2.4
2.4
|
L
 -1.2%
H
2.4
2.6
|
L
 -17.4%
H
2.3
3.1
|
L
 -31.9%
H
2.3
3.9
|
L
 -32.9%
H
1.8
6.9
|
L
 133.7%
H
0.1
6.9
|
L
 -68.2%
H
0.1
13.4
|
L
 -94.6%
H
0.1
74.2
|
| Synaptogenix Inc |
|
44.3
|
6.0
|
L
 5.5%
H
5.6
6.1
|
L
 5.5%
H
5.0
6.5
|
L
 52.6%
H
3.7
6.5
|
L
 18.3%
H
3.3
6.5
|
L
 126.2%
H
1.8
12.0
|
L
 643.8%
H
0.1
12.0
|
L
 -31.8%
H
0.1
14.5
|
L
H
0.1
14.5
|
| SciSparc Ltd |
|
2.6
|
4.6
|
L
 -0.6%
H
4.2
4.6
|
L
 6.2%
H
4.2
4.7
|
L
 -1.7%
H
3.6
6.2
|
L
 -64.8%
H
3.6
14.2
|
L
 -92.8%
H
3.6
94.5
|
L
 -99.8%
H
3.6
4471.7
|
L
H
3.6
41769
|
L
H
3.6
41769
|
| ARS Pharma Inc |
|
809.1
|
8.2
|
L
 -1.0%
H
8.1
8.5
|
L
 -2.6%
H
8
9.1
|
L
 -9.2%
H
8
9.7
|
L
 -22.1%
H
8
13.2
|
L
 -42.9%
H
6.7
18.9
|
L
 -2.7%
H
2.6
18.9
|
L
 -86.4%
H
2.6
61
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
223.2
|
4.5
|
L
 1.6%
H
4.2
4.5
|
L
 6.5%
H
4.0
4.6
|
L
 61.2%
H
2.8
4.6
|
L
 242.3%
H
1.2
4.6
|
L
 71.2%
H
1.2
5.3
|
L
 1136.1%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,752.3
|
16.7
|
L
 0.2%
H
16.5
17.3
|
L
 1.8%
H
16.3
17.3
|
L
 -11.6%
H
15.5
19.3
|
L
 -20.7%
H
15.5
24.7
|
L
 -77.3%
H
10.4
76.7
|
L
 -87.3%
H
10.4
173.3
|
L
 -79.8%
H
10.4
173.3
|
L
 -7.3%
H
8
181.8
|
| Sutro Biopharma Inc |
|
338.9
|
20.7
|
L
 -2.1%
H
20.2
21.6
|
L
 -10.4%
H
20.2
25.4
|
L
 12.3%
H
17.5
26.5
|
L
 107.2%
H
9.7
26.5
|
L
 159.8%
H
5.2
26.5
|
L
 -59.5%
H
5.2
61.3
|
L
 -91.7%
H
5.2
257.8
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,750.1
|
47.8
|
L
 -2.2%
H
46.8
49.3
|
L
 -4.3%
H
46.8
51.2
|
L
 -6.1%
H
46.8
59.7
|
L
 -7.2%
H
46.8
59.7
|
L
 47.8%
H
29.2
59.7
|
L
 34.2%
H
22
59.7
|
L
 82.7%
H
22
59.7
|
L
 239.0%
H
13.1
61.3
|
| Savara Inc |
|
1,015.1
|
5.0
|
L
 -3.9%
H
4.9
5.2
|
L
 -5.5%
H
4.9
5.4
|
L
 -10.3%
H
4.9
6.1
|
L
 -18.0%
H
4.9
6.6
|
L
 73.4%
H
1.9
7
|
L
 140.8%
H
1.6
7
|
L
 139.6%
H
1.0
7
|
L
 -71.3%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
1.2
|
1.4
|
L
 -6.0%
H
1.4
1.5
|
L
 -25.9%
H
1.4
2.0
|
L
 -41.2%
H
1.4
2.7
|
L
 -13.0%
H
0.0
7.0
|
L
 -49.5%
H
0.0
7.0
|
L
 -83.0%
H
0.0
9.4
|
L
 -97.2%
H
0.0
57
|
L
H
0.0
2335
|
| Sanofi (ADR) |
|
107,313.8
|
44.6
|
L
 -1.6%
H
44.4
45.5
|
L
 2.3%
H
43.3
45.5
|
L
 -4.6%
H
43.3
48.8
|
L
 -7.4%
H
43.3
49.4
|
L
 -22.8%
H
43.3
57.6
|
L
 -7.1%
H
42.6
60.1
|
L
 -10.7%
H
36.9
60.1
|
L
 11.5%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
281.8
|
5.2
|
L
 -1.7%
H
5.2
5.4
|
L
 -1.0%
H
5.1
5.5
|
L
 -23.8%
H
5.1
7.5
|
L
 -1.1%
H
4.7
7.5
|
L
 12.8%
H
2.8
7.8
|
L
 47.2%
H
1.0
10.5
|
L
 -69.7%
H
1.0
17.7
|
L
 -98.1%
H
1.0
465.2
|
| Tarsus Pharma Inc |
|
2,745.4
|
64.5
|
L
 -3.4%
H
63.8
67.1
|
L
 -5.1%
H
63.8
70.4
|
L
 -3.2%
H
63.8
80
|
L
 -20.8%
H
60.5
84.1
|
L
 29.3%
H
38.5
85.3
|
L
 394.3%
H
11.3
85.3
|
L
 101.2%
H
10.8
85.3
|
L
H
10.8
85.3
|
| Theravance Biopharma Inc |
|
726.1
|
14.3
|
L
 2.3%
H
13.9
14.4
|
L
 4.0%
H
13.4
14.4
|
L
 -27.1%
H
13.1
19.8
|
L
 -23.7%
H
13.1
21.0
|
L
 53.1%
H
7.9
21.0
|
L
 37.3%
H
7.4
21.0
|
L
 -32.0%
H
6.1
22.7
|
L
 -20.1%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
245.9
|
14.3
|
L
 -4.1%
H
14
15.3
|
L
 3.3%
H
13.8
16.3
|
L
 16.6%
H
10.4
16.3
|
L
 9.2%
H
10.4
18.4
|
L
 122.4%
H
4.6
18.4
|
L
 -68.1%
H
2.8
61.2
|
L
 -99.6%
H
2.8
3952
|
L
 -100.0%
H
2.8
94080
|
| TG Therapeutics Inc |
|
4,801.8
|
30.1
|
L
 -1.0%
H
29.5
30.5
|
L
 7.6%
H
28.1
32.5
|
L
 1.8%
H
26.8
32.5
|
L
 -2.9%
H
26.8
33.2
|
L
 -28.2%
H
25.3
46.5
|
L
 106.0%
H
6.5
46.5
|
L
 -38.8%
H
3.5
51.3
|
L
 240.9%
H
3.3
56.7
|
| Alpha Teknova Inc |
|
149.5
|
2.8
|
L
 -2.1%
H
2.7
2.9
|
L
H
2.6
3.1
|
L
 35.4%
H
1.9
3.1
|
L
 -40%
H
1.9
4.6
|
L
 -51.0%
H
1.9
7.5
|
L
 -11.7%
H
1.2
10.4
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
154.0
|
1.2
|
L
 -4.0%
H
1.2
1.3
|
L
 -0.8%
H
1.2
1.4
|
L
 -5.5%
H
1.2
1.6
|
L
 -20.4%
H
1.2
1.8
|
L
 -6.2%
H
0.7
2.6
|
L
 49.4%
H
0.4
2.6
|
L
 -60.3%
H
0.4
3.3
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
201.1
|
15
|
L
 -4.9%
H
15.0
17
|
L
 13.3%
H
13.2
17
|
L
 6.8%
H
13.1
17
|
L
 -12.2%
H
13.1
20.0
|
L
 -17.5%
H
13.1
70.0
|
L
 -99.9%
H
0.2
12800.1
|
L
 -100.0%
H
0.2
972800
|
L
 -100.0%
H
0.2
2412800000
|
| Tenaya Therapeutics Inc |
|
162.7
|
0.8
|
L
 -6.3%
H
0.8
0.8
|
L
 -11.8%
H
0.7
0.9
|
L
 21.0%
H
0.5
1.0
|
L
 7.1%
H
0.5
1.0
|
L
 13.6%
H
0.4
2.4
|
L
 -71.3%
H
0.4
8.1
|
L
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
30.9
|
2.3
|
L
 6.0%
H
2.1
2.3
|
L
 1.3%
H
2.1
2.3
|
L
 -4.6%
H
2.1
2.5
|
L
 -26.6%
H
2.1
3.2
|
L
 182.7%
H
0.4
12.2
|
L
 81.7%
H
0.2
12.2
|
L
 -93.4%
H
0.2
41
|
L
 -99.9%
H
0.2
2623.5
|
| Travere Therapeutics Inc |
|
2,475.8
|
26.8
|
L
 -3.2%
H
26.2
27.8
|
L
 -3.5%
H
26.2
28.5
|
L
 -11.7%
H
26.2
31.5
|
L
 -22.2%
H
22.6
42.1
|
L
 28.9%
H
12.9
42.1
|
L
 27.9%
H
5.1
42.1
|
L
 0.6%
H
5.1
42.1
|
L
 93.2%
H
5.1
42.1
|
| TherapeuticsMD Inc |
|
25.9
|
2.2
|
L
 0.5%
H
2.2
2.3
|
L
 3.2%
H
2.2
2.3
|
L
 -2.6%
H
2.1
2.4
|
L
 31.8%
H
1.6
3.0
|
L
 166.7%
H
0.8
3.0
|
L
 -37.3%
H
0.7
4.7
|
L
 -97.1%
H
0.7
78.8
|
L
 -99.3%
H
0.7
464.5
|
| Universe Pharma INC |
|
1.4
|
2.4
|
L
 -2.4%
H
2.3
2.4
|
L
 -5.5%
H
2.3
2.7
|
L
 -17.8%
H
2
3.0
|
L
 -35.7%
H
2
7.2
|
L
 -32.6%
H
0.1
11
|
L
 -72.9%
H
0.1
64.8
|
L
H
0.1
179.9
|
L
H
0.1
179.9
|
| United Therapeutics Corp |
|
22,978.0
|
524.3
|
L
 -0.5%
H
520
529.9
|
L
 -2.2%
H
520
541.2
|
L
 10.7%
H
466
548.1
|
L
 1.4%
H
455.6
548.1
|
L
 67.2%
H
267.0
548.1
|
L
 132.9%
H
204.4
548.1
|
L
 208.2%
H
158.4
548.1
|
L
 327.0%
H
74.3
548.1
|
| Vericel Corp |
|
1,594.5
|
31.4
|
L
 -4.1%
H
31.3
33.4
|
L
 -3.5%
H
31.3
33.5
|
L
 -17.5%
H
31.2
38.7
|
L
 -12.9%
H
31.2
41.7
|
L
 -33.4%
H
29.2
48.7
|
L
 4.9%
H
28.0
63
|
L
 -47.2%
H
17.3
68.9
|
L
 581.3%
H
2.0
68.9
|
| Veru Inc |
|
36.4
|
2.3
|
L
 -0.9%
H
2.2
2.4
|
L
 -5.0%
H
2.2
2.5
|
L
 -9.2%
H
2.2
2.7
|
L
 -2.2%
H
2.1
2.8
|
L
 -55.1%
H
2.1
7.4
|
L
 -86.9%
H
2.1
19.2
|
L
 -98.4%
H
2.1
245.5
|
L
 -89.2%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
99.9
|
3
|
L
 10.3%
H
2.7
3.1
|
L
 -2.0%
H
2.7
3.4
|
L
 2.4%
H
2.7
3.5
|
L
 -53.5%
H
2.6
6.8
|
L
 -56.1%
H
2.6
9.5
|
L
 900%
H
0.1
29.3
|
L
 -47.6%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
3,735.9
|
32.3
|
L
 -4.7%
H
31.5
34.4
|
L
 -9.3%
H
31.5
36.6
|
L
 4.2%
H
30.2
37.5
|
L
 -8.1%
H
25.8
37.8
|
L
 14.0%
H
18.9
43.2
|
L
 178.0%
H
8.3
99.4
|
L
 414.0%
H
2.0
99.4
|
L
 1813.0%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
420.8
|
7.1
|
L
 -16.9%
H
7.1
8.7
|
L
 -19.2%
H
7.1
9.1
|
L
 23.6%
H
7.1
9.9
|
L
 5.5%
H
5.7
9.9
|
L
 44.7%
H
3.8
9.9
|
L
 7.9%
H
3.3
9.9
|
L
 -59.2%
H
3.3
21.9
|
L
 -7.9%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
93.6
|
5.5
|
L
 -6.0%
H
5.4
6.0
|
L
 -10.8%
H
5.4
6.5
|
L
 -5.9%
H
5
6.6
|
L
 -30.3%
H
5
9.0
|
L
 793.4%
H
0.4
9.8
|
L
 -19.1%
H
0.4
11.4
|
L
 -65.6%
H
0.4
17
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
2,757.5
|
27.0
|
L
 -3.1%
H
27.0
28.1
|
L
 -5.9%
H
27.0
29.3
|
L
 -1.7%
H
26.3
30.8
|
L
 -15.5%
H
26.3
34.3
|
L
 76.1%
H
9.9
34.3
|
L
 -3.8%
H
9.9
34.3
|
L
 50.1%
H
9.5
39
|
L
 -77.1%
H
4.7
270
|
| Vertex Pharma |
|
115,331.5
|
454
|
L
 -0.9%
H
452.9
461.1
|
L
 -3.3%
H
449.8
476.2
|
L
 -4.8%
H
449.8
507.9
|
L
 -0.5%
H
429
507.9
|
L
 -11.0%
H
362.5
514.0
|
L
 51.9%
H
297.8
519.9
|
L
 110.1%
H
176.4
519.9
|
L
 450.2%
H
71.5
519.9
|
| Viatris |
|
15,198.4
|
13.2
|
L
 -2.2%
H
13.1
13.6
|
L
 -2.3%
H
13.1
13.9
|
L
 -17.1%
H
13.1
16.5
|
L
 10.7%
H
11.8
16.5
|
L
 39.8%
H
6.9
16.5
|
L
 39.8%
H
6.9
16.5
|
L
 -10.7%
H
6.9
16.5
|
L
 -70.7%
H
6.9
50.4
|
| vTv Therapeutics Inc (Class A) |
|
141.8
|
36
|
L
 0.1%
H
35.1
37.9
|
L
 8.2%
H
32.9
39.4
|
L
 5.0%
H
31.2
41.7
|
L
 0.0%
H
28.8
44
|
L
 104.6%
H
14
44
|
L
 4636.8%
H
0.4
44
|
L
 1158.7%
H
0.4
44
|
L
 514.3%
H
0.4
44
|
| VYNE Therapeutics Inc |
|
21.0
|
0.6
|
L
 1.6%
H
0.6
0.6
|
L
 6.8%
H
0.6
0.6
|
L
 5%
H
0.6
0.6
|
L
 6.8%
H
0.6
0.6
|
L
 -62.5%
H
0.3
2.0
|
L
 -75.3%
H
0.3
8.7
|
L
 -99.6%
H
0.3
141.3
|
L
H
0.3
2869.9
|
| Vaccitech PLC (ADR) |
|
24.3
|
0.6
|
L
H
0.6
0.7
|
L
H
0.6
0.7
|
L
 1.6%
H
0.6
0.7
|
L
 -14.9%
H
0.6
0.8
|
L
 -33.0%
H
0.6
2.9
|
L
 -78.1%
H
0.6
5.1
|
L
H
0.6
18.0
|
L
H
0.6
18.0
|
| Xenetic Biosciences Inc |
|
7.5
|
3.3
|
L
 7.6%
H
3.0
3.3
|
L
 16.0%
H
2.8
3.5
|
L
 44.9%
H
2.2
3.5
|
L
 51.6%
H
2.0
3.5
|
L
 -4.1%
H
1.9
13.9
|
L
 -22.4%
H
1.9
13.9
|
L
 -87.1%
H
1.9
56.8
|
L
 -99.7%
H
1.9
1227.6
|
| Xenon Pharma Inc |
|
5,242.8
|
54.9
|
L
 -0.4%
H
54.5
56.0
|
L
 -0.5%
H
53.7
56.5
|
L
 30.1%
H
41.1
64.0
|
L
 24.6%
H
39.3
64.0
|
L
 57.7%
H
26.7
64.0
|
L
 58.8%
H
26.7
64.0
|
L
 190.5%
H
14.7
64.0
|
L
 668.4%
H
2.1
64.0
|
| Xilio Therapeutics Inc |
|
577.4
|
7.9
|
L
 7.8%
H
7.2
8.0
|
L
 10.1%
H
6.7
8.1
|
L
 -1.1%
H
6.5
8.2
|
L
 -16.1%
H
6.5
10.4
|
L
 -28.4%
H
6.5
16.5
|
L
 -80.4%
H
6.5
51.4
|
L
H
6.5
391.3
|
L
H
6.5
391.3
|
| XOMA Corp |
|
341.3
|
28.7
|
L
 -0.2%
H
28.3
29.7
|
L
 8.8%
H
26.1
30.1
|
L
 11.2%
H
24.5
30.1
|
L
 13.1%
H
22.3
30.8
|
L
 36.3%
H
18.4
39.9
|
L
 46.2%
H
13.5
39.9
|
L
 -17.5%
H
13.5
42.0
|
L
 71.9%
H
4.0
46.3
|
| XORTX Therapeutics Inc |
|
2.8
|
0.4
|
L
 -2.4%
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 2.6%
H
0.4
0.5
|
L
 -33.3%
H
0.4
0.6
|
L
 -61.2%
H
0.4
1.4
|
L
 -16.7%
H
0.3
7
|
L
 -83.0%
H
0.3
8.2
|
L
H
0.3
8.2
|
| Zevra Therapeutics Inc |
|
541.9
|
9.2
|
L
 -1.8%
H
9.2
9.5
|
L
 -7.5%
H
9.2
10.7
|
L
 4.9%
H
8.4
11.4
|
L
 11.1%
H
8.1
11.4
|
L
 15.2%
H
6.2
13.2
|
L
 86.5%
H
3.9
13.2
|
L
 -17.0%
H
3.9
15.7
|
L
 -96.0%
H
1.9
316
|
| Zymeworks BC Inc |
|
1,732.7
|
23.3
|
L
 -2.4%
H
23.3
24.2
|
L
 1.9%
H
23.1
24.3
|
L
 2.6%
H
21.9
28
|
L
 -14.4%
H
21.9
28
|
L
 80.4%
H
9.0
28.5
|
L
 173.7%
H
6.0
28.5
|
L
 -33.4%
H
4.1
39.4
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
157.1
|
4.8
|
L
 -0.2%
H
4.8
5.0
|
L
 -7.5%
H
4.6
5.3
|
L
 -9.4%
H
4.6
6.3
|
L
 -23.3%
H
4.6
7.2
|
L
 19.0%
H
1.7
11.4
|
L
 -36.7%
H
1.7
20.7
|
L
 -36.7%
H
1.7
20.7
|
L
 -36.7%
H
1.7
20.7
|
| CervoMed Inc |
|
37.2
|
4.0
|
L
 -5.0%
H
3.9
4.3
|
L
 -5.4%
H
3.9
4.6
|
L
 -13.2%
H
3.6
5.1
|
L
 -47.1%
H
3.6
8.6
|
L
 -65.2%
H
3.6
16.9
|
L
 -55.2%
H
1.8
26.4
|
L
 -94.7%
H
1.8
80.3
|
L
 -100.0%
H
1.8
17437.5
|
| Dianthus Therapeutics Inc |
|
3,361.0
|
77.8
|
L
 -2.8%
H
75.8
82.5
|
L
 -0.1%
H
75.8
82.5
|
L
 56.9%
H
48.9
88.0
|
L
 83.2%
H
35.8
88.0
|
L
 280.4%
H
13.4
88.0
|
L
 10131.6%
H
6.6
88.0
|
L
 10131.6%
H
6.6
88.0
|
L
 10131.6%
H
6.6
88.0
|
| Neumora Therapeutics Inc |
|
426.5
|
2.5
|
L
 -2.3%
H
2.5
2.6
|
L
 -16.3%
H
2.5
3.1
|
L
 -26.0%
H
2.5
3.6
|
L
 43.4%
H
1.5
3.7
|
L
 116.4%
H
0.6
3.7
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Agape ATP Corp |
|
2.2
|
2.2
|
L
 -8.4%
H
2.2
2.4
|
L
 -50.7%
H
2.2
4.2
|
L
 2.8%
H
1.7
6.3
|
L
 -64.1%
H
1.7
7.3
|
L
 -95.7%
H
1.7
128.3
|
L
 -99.9%
H
1.7
1590
|
L
 -99.9%
H
1.7
1590
|
L
 -99.9%
H
1.7
1590
|
| Barinthus Biotherapeutics PLC. (ADR) |
|
25.7
|
0.6
|
L
H
0.6
0.7
|
L
H
0.6
0.7
|
L
 1.6%
H
0.6
0.7
|
L
 -14.9%
H
0.6
0.8
|
L
 -37.6%
H
0.6
2.9
|
L
 -82.7%
H
0.6
5.1
|
L
 -82.7%
H
0.6
5.1
|
L
 -82.7%
H
0.6
5.1
|
| Viamet Pharma Corp |
|
1,060.6
|
10.1
|
L
 -1.9%
H
10.0
10.5
|
L
 -5.1%
H
9.9
11.8
|
L
 -4.2%
H
9.9
12.1
|
L
 -4.2%
H
9.9
12.1
|
L
 -4.2%
H
9.9
12.1
|
L
 -4.2%
H
9.9
12.1
|
L
 -4.2%
H
9.9
12.1
|
L
 -4.2%
H
9.9
12.1
|
| Onconetix Inc |
|
1.0
|
0.6
|
L
 29.2%
H
0.5
0.6
|
L
 14.8%
H
0.5
0.6
|
L
 -18.4%
H
0.4
1.0
|
L
 -65.0%
H
0.4
2.3
|
L
 376.9%
H
0.1
5.9
|
L
 -98.5%
H
0.1
63.2
|
L
 -65.9%
H
0.1
3636
|
L
 -65.9%
H
0.1
3636
|
| Talphera Inc |
|
38.7
|
0.8
|
L
 2.5%
H
0.8
0.9
|
L
 3.8%
H
0.8
0.9
|
L
 6.4%
H
0.8
1
|
L
 -24.6%
H
0.8
1.3
|
L
 33.9%
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| ArriVent BioPharma Inc |
|
973.3
|
22.0
|
L
 -3.7%
H
21.9
23.1
|
L
 -7.9%
H
21.9
24.9
|
L
 -4.2%
H
21.9
27.2
|
L
 0.1%
H
18.2
27.2
|
L
 12.7%
H
15.5
27.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
| Skye Bioscience Inc |
|
20.8
|
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -16.7%
H
0.6
0.8
|
L
 -30.1%
H
0.6
1.2
|
L
 -65.6%
H
0.6
5.8
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
| Actuate Therapeutics Inc |
|
54.6
|
2.4
|
L
 -6%
H
2.3
2.7
|
L
 -8.2%
H
2.3
2.8
|
L
 -43.1%
H
2.3
4.4
|
L
 -66.3%
H
2.3
7.3
|
L
 -66.4%
H
2.3
12.0
|
L
H
2.3
12.0
|
L
H
2.3
12.0
|
L
H
2.3
12.0
|
| Bicara Therapeutics Inc |
|
1,192.9
|
18.4
|
L
 -2.0%
H
17.9
19.5
|
L
 -4.1%
H
17.9
20.0
|
L
 18.9%
H
15.1
20.3
|
L
 4.6%
H
13.8
20.3
|
L
 40.6%
H
7.8
20.3
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
| Gelteq Ltd |
|
8.1
|
0.8
|
L
 2.7%
H
0.7
0.8
|
L
 -2.6%
H
0.7
0.8
|
L
 2.7%
H
0.6
0.8
|
L
 -15.6%
H
0.6
1.4
|
L
 -22.5%
H
0.6
4.1
|
L
H
0.6
5.5
|
L
H
0.6
5.5
|
L
H
0.6
5.5
|
| Septerna Inc |
|
1,085.8
|
24.2
|
L
 -0.4%
H
23.8
24.5
|
L
 -3.8%
H
23.4
27
|
L
 -11.4%
H
23.4
32.6
|
L
 -18.3%
H
23.0
32.6
|
L
 293.2%
H
4.7
32.6
|
L
H
4.2
32.6
|
L
H
4.2
32.6
|
L
H
4.2
32.6
|
| Alpha Cognition Inc |
|
124.1
|
5.7
|
L
 -2.2%
H
5.7
6.2
|
L
 -0.7%
H
5.6
6.2
|
L
 -2.4%
H
5.3
6.5
|
L
 2.7%
H
4.5
6.9
|
L
 2.9%
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
| Atlantic Intl Corp |
|
316.1
|
4.5
|
L
 1.6%
H
4.2
4.5
|
L
 6.5%
H
4.0
4.6
|
L
 61.2%
H
2.8
4.6
|
L
 242.3%
H
1.2
4.6
|
L
 71.2%
H
1.2
5.3
|
L
 71.2%
H
1.2
5.3
|
L
 71.2%
H
1.2
5.3
|
L
 71.2%
H
1.2
5.3
|
| BeiGene Ltd (ADR) |
|
30,556.1
|
275.3
|
L
 -2.6%
H
275.0
285.5
|
L
 -3.1%
H
275.0
293.1
|
L
 -24.0%
H
275.0
372.7
|
L
 -12.9%
H
275.0
372.7
|
L
 4.8%
H
196.5
385.2
|
L
 49.0%
H
172.7
385.2
|
L
 49.0%
H
172.7
385.2
|
L
 49.0%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
14.5
|
0.4
|
L
 10.5%
H
0.3
0.4
|
L
H
0.3
0.4
|
L
 -19.2%
H
0.3
0.6
|
L
 -61.8%
H
0.3
1.2
|
L
 -27.6%
H
0.3
3.3
|
L
 -27.6%
H
0.3
3.3
|
L
 -27.6%
H
0.3
3.3
|
L
 -27.6%
H
0.3
3.3
|
| Ascentage Pharma Grp Intl (ADR) |
|
1,776.5
|
19.1
|
L
 -13.3%
H
19.1
21
|
L
 -21.8%
H
19.1
25
|
L
 -23.4%
H
19.1
25.5
|
L
 -34.8%
H
19.1
28.9
|
L
 -1.5%
H
17.6
48.5
|
L
 10.0%
H
17
48.5
|
L
 10.0%
H
17
48.5
|
L
 10.0%
H
17
48.5
|
| Maze Therapeutics Inc |
|
2,311.2
|
48.0
|
L
 -2.8%
H
47.8
50.7
|
L
 -4.3%
H
46.7
53.7
|
L
 8.6%
H
42.9
53.7
|
L
 15.2%
H
37.4
53.7
|
L
 301.6%
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
| Aardvark Therapeutics Inc |
|
88.6
|
4.1
|
L
 -16.9%
H
4.1
4.9
|
L
 -20.0%
H
4.1
5.5
|
L
 -67.0%
H
4.1
12.9
|
L
 -70.4%
H
4.1
16.6
|
L
 -55.7%
H
4.1
17.9
|
L
H
4.1
19.6
|
L
H
4.1
19.6
|
L
H
4.1
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
7.1
|
0.3
|
L
 -2.9%
H
0.3
0.3
|
L
 -10.8%
H
0.3
0.4
|
L
 -21.4%
H
0.3
0.4
|
L
 -26.7%
H
0.3
0.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
| Jyong Biotech Ltd |
|
126.2
|
1.7
|
L
 -5.0%
H
1.7
1.8
|
L
 -14.1%
H
1.7
2.2
|
L
 -15.4%
H
1.7
3.1
|
L
 -46.5%
H
1.4
7.8
|
L
 -83.2%
H
1.4
67
|
L
 -83.2%
H
1.4
67
|
L
 -83.2%
H
1.4
67
|
L
 -83.2%
H
1.4
67
|
| Black Titan Corp |
|
12.9
|
1.3
|
L
 -4.4%
H
1.3
1.4
|
L
 -12.8%
H
1.3
1.5
|
L
 -18.9%
H
1.3
1.6
|
L
 -39.2%
H
1.3
3.3
|
L
 -94.6%
H
1.3
23.5
|
L
 -94.6%
H
1.3
23.5
|
L
 -94.6%
H
1.3
23.5
|
L
 -94.6%
H
1.3
23.5
|
| MapLight Therapeutics Inc |
|
796.8
|
17.6
|
L
 0.4%
H
17.4
18.1
|
L
 -7.9%
H
16.3
21.5
|
L
 -1.8%
H
16.3
21.5
|
L
 -14.6%
H
15.5
21.5
|
L
 -4.3%
H
12.2
21.6
|
L
 -4.3%
H
12.2
21.6
|
L
 -4.3%
H
12.2
21.6
|
L
 -4.3%
H
12.2
21.6
|
| NovaBridge Biosciences ADR |
|
295.1
|
2.6
|
L
 -4.8%
H
2.5
2.8
|
L
 -9.5%
H
2.5
3.1
|
L
 -22.2%
H
2.5
3.9
|
L
 -38.9%
H
2.5
5.2
|
L
 -43.7%
H
2.5
5.2
|
L
 -43.7%
H
2.5
5.2
|
L
 -43.7%
H
2.5
5.2
|
L
 -43.7%
H
2.5
5.2
|
| Evommune Inc |
|
735.5
|
23.3
|
L
 -1.0%
H
22.7
24.3
|
L
 6.1%
H
22.6
25.5
|
L
 -17.6%
H
20.9
30.1
|
L
 27.8%
H
14.8
33.2
|
L
 15.3%
H
13.9
33.2
|
L
 15.3%
H
13.9
33.2
|
L
 15.3%
H
13.9
33.2
|
L
 15.3%
H
13.9
33.2
|
| Aktis Oncology Inc |
|
-
|
17.7
|
L
 -1.6%
H
16.9
18.3
|
L
 -6.8%
H
16.9
20.7
|
L
 -6.4%
H
16.9
21.6
|
L
 -21.0%
H
16.8
24.5
|
L
 -21.0%
H
16.8
24.5
|
L
 -21.0%
H
16.8
24.5
|
L
 -21.0%
H
16.8
24.5
|
L
 -21.0%
H
16.8
24.5
|
| Helus Pharma Inc |
|
230.5
|
4.6
|
L
 -4.0%
H
4.6
5.0
|
L
 -0.4%
H
4.5
5.0
|
L
 -32.2%
H
4.5
8.6
|
L
 -38.7%
H
4.5
8.6
|
L
 -38.7%
H
4.5
8.6
|
L
 -38.6%
H
4.5
8.6
|
L
 -38.6%
H
4.5
8.6
|
L
 -38.6%
H
4.5
8.6
|
| NervGen Pharma Corp |
|
310.5
|
3.9
|
L
 -1.3%
H
3.9
4.0
|
L
 8.9%
H
3.6
4.1
|
L
 -11.9%
H
3.6
4.5
|
L
 -31.8%
H
3.6
5.9
|
L
 -31.8%
H
3.6
5.9
|
L
 -31.8%
H
3.6
5.9
|
L
 -31.8%
H
3.6
5.9
|
L
 -31.8%
H
3.6
5.9
|
| Veradermics Inc |
|
2,065.7
|
58.9
|
L
 3.5%
H
55.1
59.6
|
L
 11.5%
H
52.6
63.0
|
L
 32.4%
H
39.7
63.0
|
L
 56%
H
35.1
63.0
|
L
 56%
H
35.1
63.0
|
L
 56%
H
35.1
63.0
|
L
 56%
H
35.1
63.0
|
L
 56%
H
35.1
63.0
|
| Eikon Therapeutics Inc |
|
638.1
|
11.8
|
L
 7.7%
H
11.0
12.2
|
L
 3.1%
H
10.9
13.8
|
L
 -20.6%
H
10.8
16.2
|
L
 -21.2%
H
10.8
16.5
|
L
 -21.2%
H
10.8
16.5
|
L
 -21.2%
H
10.8
16.5
|
L
 -21.2%
H
10.8
16.5
|
L
 -21.2%
H
10.8
16.5
|
| Satellos Bioscience Inc |
|
-
|
7.2
|
L
 -9.6%
H
7.1
8.0
|
L
 -9.5%
H
6.7
8.4
|
L
 -35.6%
H
6.7
13.4
|
L
 -35.6%
H
6.7
13.4
|
L
 -35.6%
H
6.7
13.4
|
L
 -35.6%
H
6.7
13.4
|
L
 -35.6%
H
6.7
13.4
|
L
 -35.6%
H
6.7
13.4
|